

Palladium catalyzed stereocontrolled synthesis of *C*-aryl glycosides using arenediazonium salts at room temperature

Adesh Kumar Singh and Jeyakumar Kandasamy*

Department of chemistry, Indian Institute of Technology (BHU), Varanasi,
Uttar Pradesh-221005
Email: jeyakumar.chy@iitbhu.ac.in

List of Contents

1. Experiment Section.....	SI-1
2. ¹ H and ¹³ C NMR of glycoside 1aa-1aj	SI-39
3. ¹ H and ¹³ C NMR of glycoside 3aa-3ce	SI-57
4. ¹ H and ¹³ C NMRs of glycoside 4ab	SI-169
5. ¹ H and ¹³ C NMRs of glycosides 4ba, 4bf and 5ba	SI-171
6. ¹ H and ¹³ C NMRs of glycoside mixture of 3ab+5ab	SI-177

1. EXPERIMENTAL SECTION

General methods

All the reactions were carried out using oven dried glasswares. Solvents were evaporated with the help of rotary evaporator keeping the bath temperature below 50 °C. Thin layer chromatography was performed using pre-coated plates contained from E. Merck (TLC silica gel 60 F254). TLC plates were visualized by exposure to ultraviolet light (UV), then further analyzed by charring in stain solution (5% H₂SO₄ in MeOH). The column chromatography was performed on silica gel (100-200 mesh) using a mixture of ethyl acetate and hexane as an eluent. The NMR spectra were recorded on Bruker Avance 500 MHz NMR spectrometer. HRMS spectra were recorded on UHD Q-TOF using water's Quattro Micro V 4.1. The TMS signals were taken as the reference 0.00 ppm for ¹H NMR spectra and 77.0 ppm for ¹³C NMR spectra in CDCl₃. Sometimes the residual solvent CDCl₃ signal at 7.26 ppm was used as an internal standard for ¹H NMR spectra. Starting materials were purchased or prepared

using literature procedures as stated below. Solvents and chemicals were purchased from commercial sources and used without further purification. The palladium catalysts were purchased from Sigma Aldrich.

Preparation of 3,4,6-tri-*O*-methyl-D-glucal (1aa**):¹**

The commercially available 3,4,6-tri-*O*-acetyl-D-glucal (**1ae**) (5 g, 18.3 mmol) was stirred in MeOH (150 mL) at 0°C to which NaOMe (108 mg, 2.0 mmol) was added. The mixture was stirred for 3 h and the solvent was evaporated to dryness. To the same flask, dry DMF (100 mL) was added and cooled to 0 °C after which NaH (3.6 g, 60% in mineral oil, 91 mmol) was added portion wise. The resulting mixture was stirred for 30 min at the same temperature to which methyl iodide (5.2 mL, 80 mmol) was added slowly dropwise. The resulting mixture was stirred for overnight and quenched by saturated aqueous NH₄Cl (15 mL) and diluted with ethyl acetate (500 mL). The organic phase was washed with H₂O, brine, dried over anhydrous Na₂SO₄ and evaporated under reduced pressure. The crude product was purified by column chromatography (SiO₂, hexane:ethyl acetate = 4:1) to afford **1aa** as a colorless oil in 80% yield (2.45 g). NMR spectra were identical with literature data.¹ ¹H NMR (500 MHz, CDCl₃) δ 6.34 (d, *J* = 5.5 Hz, 1H), 4.78-4.77 (m, 1H), 3.91 (m, 1H), 3.83 (m, 1H), 3.64-3.57 (m, 2H), 3.49 (s, 3H), 3.41 (t, *J* = 7.0 Hz, 1H), 3.36-3.35 (m, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 144.4, 99.4, 76.5, 76.1, 75.7, 70.6, 59.1, 59.0, 55.6.

Preparation of tri-*O*-benzyl-D-glucal (1ab**):¹**

The commercially available 3,4,6-tri-*O*-acetyl-D-glucal (1 g, 3.6 mmol) was stirred in MeOH (30 mL) at 0°C to which NaOMe (22 mg, 0.2 mmol) was added. The mixture was stirred for 3 h and the solvent was evaporated to dryness. To the same flask, dry DMF (15 mL) was added and cooled to 0 °C followed by NaH (720 mg, 60% in mineral oil, 18 mmol) was added portion wise. The mixture was stirred for 20 min at the same temperature to which benzyl bromide (1.8 mL, 16 mmol) was added slowly drop wise. The resulting mixture was stirred for overnight and quenched by saturated aqueous NH₄Cl (6 mL) and diluted with ethyl acetate (250 mL). The organic phase was washed with H₂O, brine, dried over anhydrous Na₂SO₄ and evaporated under reduced pressure. The crude product was purified by column chromatography (SiO₂, hexane:ethyl acetate = 20:1) to afford **1ab** as a white solid in 87% yield (1.3 g). NMR spectra were identical with literature data.¹ ¹H NMR (500 MHz, CDCl₃)

δ 7.38-7.26 (m, 15H), 6.43 (d, J = 5.5 Hz, 1H), 4.89-4.88 (m, 1H), 4.84 (d, J = 11.5 Hz, 1H), 4.65 (d, J = 12.0 Hz, 2H), 4.59-4.55 (m, 3H), 4.22 (m, 1H), 4.07 (m, 1H), 3.87 (t, J = 7.0 Hz, 1H), 3.83-3.76 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 144.6, 138.3, 138.1, 137.9, 128.3, 128.3, 128.3, 127.8, 127.7, 127.7, 127.6, 99.9, 76.7, 75.7, 74.3, 73.7, 73.4, 70.4, 68.4.

Preparation of 3,4,6-tri-*O*-ethyl-D-glucal (**1ac**):¹⁵

The compound **1ac** is prepared using the literature procedure employed for the preparation of **1aa**.¹ To a solution of commercially available 3,4,6-tri-*O*-acetyl-D-glucal **1ag** (500 mg, 1.8 mmol) in MeOH (15 mL), NaOMe (10.8 mg, 0.2 mmol) was added at 0°C. The mixture was stirred for 3 h and evaporated to dryness. To the same flask, dry DMF (10 mL) was added and cooled to 0 °C followed by NaH (360 mg, 60% in mineral oil, 9 mmol) was added portion wise. The mixture was stirred for 20 min at the same temperature to which ethyl bromide (0.6 mL, 9 mmol) was added slowly drop wise. The resulting mixture was stirred for overnight and quenched by saturated aqueous NH_4Cl (3 mL) and diluted with ethyl acetate (180 mL). The organic phase was washed with H_2O , brine, dried over anhydrous Na_2SO_4 and evaporated under reduced pressure. The crude product was purified by column chromatography (SiO_2 , hexane:ethyl acetate = 4:1) to afford **1ac** as a colorless oil in 75% yield (310 mg). NMR spectra were identical with literature data.² ^1H NMR (500 MHz, CDCl_3) δ 6.34 (d, J = 5.5 Hz, 1H), 4.76-4.75 (m, 1H), 3.95-3.90 (m, 2H), 3.81 (t, J = 7.5, 1H), 3.68 (s, 2H), 3.65-3.61 (m, 2H), 3.57-3.48 (m, 4H), 1.20-1.17 (m, 9H). ^{13}C NMR (125 MHz, CDCl_3) δ 144.3, 100.4, 76.8, 76.0, 74.7, 68.9, 67.1, 66.8, 63.9, 15.6, 15.5, 15.0.

Preparation of 3,4,6-tri-*O*-methoxymethyl-D-glucal (**1ad**):³

To a solution of commercially available 3,4,6-tri-*O*-acetyl-D-glucal **1ag** (500 mg, 1.8 mmol) in MeOH (15 mL), NaOMe (10.8 mg, 0.2 mmol) was added at 0°C. The mixture was stirred for 3 h and evaporated to dryness to obtain crude D-glucal. It was purified by a short silica chromatography using DCM-methanol. The pure D-glucal was dissolved in anhydrous DCM (20 mL) and cooled to 0°C after which diisopropylethyl amine (2.0 mL, 11 mmol) was added followed by the dropwise addition of chloromethyl methyl ether (0.8 mL). The reaction mixture was allowed to stir for 12 h at room temperature and again diisopropylethyl amine (2.0 mL, 11 mmol) was added followed by the

dropwise addition of chloromethyl methyl ether (0.8 mL). Further the reaction was allowed to stir for 12 h and diluted with DCM (100 mL). The organic layer was washed with solution of 1M HCl (50 mL), NaHCO₃ (50 mL), dried over anhydrous Na₂SO₄, and evaporated under reduced pressure. The crude product was purified by column chromatography (SiO₂, hexane:ethyl acetate = 20:1) to afford **1ad** as a colorless oil in 60% yield (300 mg). NMR spectra were identical with literature data.³ ¹H NMR (500 MHz, CDCl₃) δ 6.37(d, *J* = 5.5 Hz, 1H), 4.84 (m, 1H), 4.78 (d, *J* = 6.0 Hz, 1H), 4.71 (d, *J* = 6.5 Hz, 1H), 4.67 (s, 2H), 4.63 (s, 2H), 4.13-4.08 (m, 2H), 3.83-3.77 (m, 3H), 3.37 (s, 3H), 3.34 (s, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 144.1, 99.9, 96.6, 96.5, 95.3, 76.1, 72.5, 71.6, 65.7, 55.9, 55.4, 55.2.

Preparation of 3,4,6-tri-*O*-methyl-D-galactal (1af**):¹**

The commercially available 3,4,6-tri-*O*-acetyl-D-galactal (**1ae**) (2 g, 7.2 mmol) was stirred in MeOH (40 mL) at 0°C to which NaOMe (44 mg, 0.8 mmol) was added. The mixture was stirred for 3 h and the solvent was evaporated to dryness. To the same flask, dry DMF (25 mL) was added and cooled to 0 °C to which NaH (1.5 g, 60% in mineral oil, 36 mmol) was added portion wise. The mixture was stirred for 30 min at the same temperature to which methyl iodide (2.6 mL, 40 mmol) was added slowly drop wise. The resulting mixture was stirred for overnight and quenched by saturated aqueous NH₄Cl (7 mL) and diluted with ethyl acetate (250 mL). The organic phase was washed with H₂O, brine, dried over anhydrous Na₂SO₄ and evaporated under reduced pressure. The crude product was purified by column chromatography (SiO₂, hexane:ethyl acetate = 4:1) to afford **1af** as a colorless oil in 74% yield (1.05 g). NMR spectra were identical with literature data.¹ ¹H NMR (500 MHz, CDCl₃) δ 6.28 (d, *J* = 6.0 Hz, 1H), 4.77-4.75 (m, 1H), 4.11 (m, 1H), 3.92 (s, 1H), 3.65-3.63 (m, 2H), 3.55-3.52 (m, 1H), 3.50 (s, 3H), 3.36 (s, 3H), 3.34 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 143.8, 99.1, 74.9, 73.4, 72.1, 70.3, 59.6, 58.9, 56.4.

Preparation of 3,4,6-tri-*O*-benzyl-D-galactal (1ag**):¹**

The commercially available 3,4,6-tri-*O*-acetyl-D-galactal (1 g, 3.6 mmol) was stirred in MeOH (25 mL) at 0°C to which NaOMe (22 mg, 0.4 mmol) was added. The mixture was stirred for 3 h and the solvent was evaporated to dryness. To the same flask, dry DMF (10 mL) was added and cooled to 0 °C followed by NaH (720 mg, 60% in mineral oil, 18 mmol) was added portion wise. The mixture was stirred for 20 min at the

same temperature to which benzyl bromide (1.8 mL, 16 mmol) was added slowly dropwise. The resulting mixture was stirred for overnight and quenched by saturated aqueous NH_4Cl (3 mL) and diluted with ethyl acetate (250 mL). The organic phase was washed with H_2O , brine, dried over anhydrous Na_2SO_4 and evaporated under reduced pressure. The crude product was purified by column chromatography (SiO_2 , hexane:ethyl acetate = 9:1) to afford **1ag** as a white solid in 73% yield (1.1 g). NMR spectra were identical with literature data.¹ ^1H NMR (500 MHz, CDCl_3) δ 7.40-7.32 (m, 15H), 6.43 (d, J = 6.0 Hz, 1H), 4.95-4.92 (m, 2H), 4.71-4.65 (m, 3H), 4.56 (d, J = 12.0 Hz, 1H), 4.48 (d, J = 12.0 Hz, 1H), 4.24 (m, 2H), 4.00 (s, 1H), 3.85 (t, J = 9.0 Hz, 1H), 3.72 (dd, J = 9.5, 4.5 Hz, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ 144.0, 138.3, 138.2, 137.8, 128.2, 128.2, 128.0, 127.7, 127.5, 127.4, 127.3, 99.8, 75.5, 73.2, 73.1, 71.1, 70.7, 70.6, 68.3.

Preparation of 3,4-di-*O*-benzyl-L-rhamnal (**1ah**):⁴

L-Rhamnose (5.0 g, 30.5 mmol) was suspended in acetic anhydride (22 mL) and cooled to 0 °C after which perchloric acid (0.25 mL) was added dropwise. The mixture was allowed to stir for 3 h at room temperature and cooled to 0 °C to which hydrobromic acid (44 mL, 33% in AcOH) was added dropwise. The resulting mixture was stirred for overnight at room temperature and concentrated. The crude glycopyranosyl bromide was dissolved in CH_3CN and then Zinc dust (15 g, 228 mmol) and ammonium chloride (12 g, 228 mmol) were added and stirred at 60 °C for 2.5 h. Upon completion of the reaction, the reaction mixture is filtrated and the filtrate was concentrated and purified by column chromatography (SiO_2 , hexane:ethyl acetate = 2:1) to afford 3,4-di-*O*-acetyl-L-rhamnose as colorless oil in 75% yield (4.9 g). NMR spectra were identical with literature.^{18a} To a solution of 3,4-di-*O*-acetyl-L-rhamnal (1 g, 4.6 mmol) in THF (30 mL), NaOH (736 mg, 18.4 mmol), TBAI (50 mg, 0.13 mmol) and benzyl bromide (2.2 mL, 18.4 mmol) were added successively and the reaction mixture was allowed to stir for 5 h at room temperature. After completion, the reaction mixture was diluted with water and extracted with DCM. The organic layer was washed with water, dried over anhydrous Na_2SO_4 , and evaporated. The crude residue was purified by column chromatography (SiO_2 , hexane:ethyl acetate = 2:1) to afford 3,4-di-*O*-benzyl-L-rhamnose **1ah** as colourless oil in 50% yield (720 g).^{4b} NMR spectra were identical with literature data.¹⁵ ^1H NMR (500 MHz, CDCl_3) δ 7.39-7.31 (m, 10H), 6.39 (d, J = 5.5 Hz, 1H), 4.92-4.88 (m, 2H), 4.73 (d, J = 11.5 Hz, 1H), 4.69 (d, J = 11.5 Hz, 1H), 4.60

(d, $J = 11.5$ Hz, 1H), 4.24 (d, $J = 6.0$ Hz, 1H), 3.99-3.97 (m, 1H), 3.51 (t, $J = 7.5$ Hz, 1H), 1.41 (d, $J = 6.5$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 144.7, 138.3, 138.2, 128.3, 127.9, 127.7, 127.7, 127.5, 100.0, 79.4, 76.3, 74.0, 73.9, 70.4, 17.4.

Preparation of 3,4-di-*O*-benzyl-D-xylal (**1ai**):⁴


D-xylose (5.0 g, 33.5 mmol) was suspended in acetic anhydride (25 mL), perchloric acid (0.3 mL) was added dropwise at 0 °C. The mixture was allowed to stir for 3 h at room temperature and cooled to 0 °C to which hydrobromic acid (48 mL, 33% in AcOH) was added dropwise. The resulting mixture was stirred for overnight at room temperature and concentrated. The crude glycopyranosyl bromide was dissolved in CH_3CN and then Zinc dust (15 g, 228 mmol) and ammonium chloride (12 g, 228 mmol) were added and stirred at 60°C for 2.5 h. Upon completion of the reaction, the reaction mixture is filtrated and the filtrate was concentrated and purified by column chromatography (SiO_2 , hexane:ethyl acetate = 2:1) to afford 3,4-di-*O*-acetyl-D-xylal as colorless oil in 50% yield (3.3 g).^{4a} To a solution of 3,4-di-*O*-acetyl- D-xylal (1 g, 5 mmol) in THF (30 mL), NaOH (736 mg, 18.4 mmol), TBAI (50 mg, 0.13 mmol) and benzyl bromide (2.2 mL, 18.4 mmol) were added successively and the reaction mixture was allowed to stir for 3 h at room temperature. After completion, the reaction mixture was diluted with water and extracted with DCM. The organic layer was washed with water, dried over anhydrous Na_2SO_4 , and evaporated. The crude residue was purified by column chromatography (SiO_2 , hexane:ethyl acetate = 9:1) to afford 3,4-di-*O*-benzyl-D- xylal **1ai** as colourless oil in 51% yield (743 mg).^{18b} NMR spectra were identical with literature data.⁵ ^1H NMR (500 MHz, CDCl_3) δ 7.36-7.30 (m, 10H), 6.57 (d, $J = 5.5$ Hz, 1H), 4.96 (m, 1H), 4.68-4.65 (m, 2H), 4.62 (d, $J = 11.5$ Hz, 1H), 4.54 (d, $J = 11.5$ Hz, 1H), 4.13 (d, $J = 11.5$ Hz, 1H), 3.98 (d, $J = 12.0$ Hz, 1H), 3.86 (s, 1H), 3.69 (s, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ 146.6, 138.3, 137.8, 128.4, 128.3, 127.8, 127.7, 127.6, 127.6, 98.9, 72.6, 71.2, 69.9, 69.0, 63.9.

Preparation of 3,5-di-*O*-benzyl-D-ribal (**1aj**):⁶

D-Ribose (3.0 g., 20 mmol) was suspended in DCM (20 mL) to which acetic anhydride (11.23 g., 110 mmol) followed by pyridine (9.49 g., 120 mmol) was added at 0 °C. The resulting mixture was stirred for 12 hours at room temperature and quenched with water (20 mL). The aqueous layer was extracted with DCM (2X30 mL), washed with water, dried over saturated Na_2SO_4 and concentrated. The crude product was purified

by short silica chromatography using 20% ethyl acetate in hexane to obtain D-ribofuranose 1,2,3,5-tetraacetate. Further, the ribose tetra-acetate was dissolved in HBr solution (33 wt % in acetic acid, 10.36 mL, 60 mmol) and stirred for 5 hours at room temperature. The reaction mixture was diluted with acetonitrile (25 mL) to which sodium acetate (3.28 g., 40 mmol), ammonium chloride (3.21 g., 60 mmol), and zinc dust (3.93 g., 40 mmol) were added successively. The reaction is allowed to stir for 2 hours at room temperature, then quenched with water, extracted with ethyl acetate (3X25 mL). The organic layer was washed with water, dried over anhydrous Na₂SO₄ and concentrated. The crude residue was purified by column chromatography (SiO₂, hexane:ethyl acetate = 9:1) to obtain 3,5-di-*O*-acetyl-D-ribal in 27.5 % yield. (1.1 g).²⁰ To a solution of 3,5-di-*O*-acetyl-D-ribal (1 g, 5 mmol) in THF (25 mL), NaOH (736 mg, 18.4 mmol), TBAI (50 mg, 0.13 mmol) and benzyl bromide (2.2 mL, 18.4 mmol) were added successively and the reaction mixture was allowed to stir for 3 h at room temperature. After completion, the reaction mixture was diluted with water and extracted with DCM. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and evaporated. The crude residue was purified by column chromatography (SiO₂, hexane:ethyl acetate = 9:1) to afford 3,5-di-*O*-benzyl-D-ribal **1aj** as colourless oil in 55% yield (801 mg). NMR spectra were identical with literature data.⁷ ¹H NMR (500 MHz, CDCl₃) δ 7.40-7.29 (m, 10H), 6.41 (d, *J* = 5.0 Hz, 1H), 4.88-4.87 (m, 1H), 4.72 (s, 2H), 4.69 (d, *J* = 12.0 Hz, 1H), 4.61 (d, *J* = 12.0 Hz, 1H), 4.09-4.39 (m, 3H), 3.76-3.74 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 146.5, 138.7, 137.9, 128.4, 128.3, 127.8, 127.7, 127.6, 127.5, 98.7, 73.1, 71.0, 70.7, 66.6, 63.2.

Preparation of aryldiazonium tetrafluoroborates:



Aryldiazonium tetrafluoroborates were prepared using literature procedure.⁸ To a stirred solution of aniline (10 mmol) in 48% aq. HBF₄ (4 ml), a solution of NaNO₂ (0.69 g in 5 ml of deionized water, 10 mmol) was added at 0 °C. The reaction mixture was stirred at 700 RPM for 30 min at 0°C. The resulting solid was filtered off, dissolved in 5 ml of acetone and precipitated by addition of 5 ml of diethyl ether. The resulting crystals

were dried in high vacuum to obtain pure aryldiazonium tetrafluoroborates. All the compounds gave identical NMR spectra to those reported previously. 4-bromobenzenediazonium tetrafluoroborate **2aa**⁸ (pink solid, 72%); 2-chlorobenzenediazonium tetrafluoroborate **2ab**⁸ (white solid, 64%); benzenediazonium tetrafluoroborate **2ac**⁸ (white solid, 70%); 1-naphthyldiazonium tetrafluoroborate **2ad**⁹ (Purple solid, 55%); 4-methylbenzenediazonium tetrafluoroborate **2ae**⁸ (white solid, 80%); 4-methoxybenzenediazonium tetrafluoroborate **2af**⁹ (white solid, 75%); 4-nitrobenzenediazonium tetrafluoroborate **2ag**⁸ (yellow solid, 69%); 4-(trifluoromethyl)benzenediazonium tetrafluoroborate **2ah**¹⁰ (white solid, 70%); 4-(methoxycarbonyl)benzenediazonium tetrafluoroborate **2ai**⁸ (white solid, 30%); 4-acetylbenzenediazonium tetrafluoroborate **2aj**⁹ (white solid, 75%); 4-cyanobenzenediazonium tetrafluoroborate **2ak**⁸ (light yellow solid, 70%); 4-fluorobenzenediazonium tetrafluoroborate **2al**⁸ (white solid, 69%); 4-chlorobenzenediazonium tetrafluoroborate **2am**¹¹ (white solid, 80%); 4-iodobenzenediazonium tetrafluoroborate **2an**¹² (brown solid, 80%); 2-ethylbenzenediazonium tetrafluoroborate **2ao**¹³ (white solid, 64%); 2,4-dimethylbenzenediazonium tetrafluoroborate **2ap**¹⁴ (white solid, 60%); 2,5-dimethylbenzenediazonium tetrafluoroborate **2aq**¹⁵ (white solid, 70%); 3-fluorobenzenediazonium tetrafluoroborate **2ar**¹⁶ (white solid, 40%); 3-chlorobenzenediazonium tetrafluoroborate **2as**⁸ (pink solid, 59%); 3-bromobenzenediazonium tetrafluoroborate **2at**¹² (orange solid, 65%); 3,5-dichlorobenzenediazonium tetrafluoroborate **2au**¹⁶ (white solid, %); 4-bromo-3-methylbenzenediazonium tetrafluoroborate **2av**¹⁴ (white solid, 30%); 3-acetylbenzenediazonium tetrafluoroborate **2aw**¹⁴ (white solid, 54%); 3-nitrobenzenediazonium tetrafluoroborate **2ax**¹⁶ (white solid, 50%); 3-(trifluoromethyl)benzenediazonium tetrafluoroborate **2ay**⁷ (Pink solid, 65%); 3,5-dimethylbenzenediazonium tetrafluoroborate **2az**¹⁶ (white solid, 20%); 2,4-dimethoxybenzenediazonium tetrafluoroborate **2ba**¹⁷ (purple solid, 60%).

General procedure used in the optimization table:

The glycal, 3,4,6-tri-*O*-methyl-D-glucal (95 mg, 0.5 mmol) was stirred in an appropriate solvent (4 mL) in a oven dried 25 ml round bottom flask. 4-Bromobenzenediazonium tetrafluoroborate (152 mg, 0.56 mmol) and palladium acetate (5.5 mg, 0.05 mmol) was successively added at room temperature under open air atmosphere. The mixture was stirred and monitored by TLC. After completion (or appropriate time mentioned in the table), the reaction mixture was diluted with ethyl acetate (150 mL) and washed with water (100 mL) and filtered, dried over anhydrous

Na₂SO₄. The organic layer was concentrated and purified by silica column chromatography (100-200 mesh) on silica gel using 20 % ethyl acetate in hexane which furnished **3aa** as white foam.

General procedure for the preparation of *C*-glycosides:

Glycal (0.25-0.5 mmol) was dissolved in acetonitrile (3 mL) to which water (1 mL) was added. To the above solution, aryldiazonium tetrafluoroborate (1.1 equiv.) and palladium acetate (5-10 mol%) was successively added at room temperature under open air atmosphere. Of the above mixture were added simultaneously aryldiazoniumtetrafluoroborate and palladium acetate at room temperature in an open air atmosphere. The reaction mixture was stirred for appropriate time (2-8 h), diluted with ethyl acetate (150 mL) and washed with water (100 mL). The organic layer was filtered, dried over anhydrous Na₂SO₄, concentrated and purified by silica column chromatography (100-200 mesh) on silica gel using ethyl acetate in hexane.

(2*R*,3*R*,6*S*)-6-(4-Bromophenyl)-3-methoxy-2-(methoxymethyl)dihydro-2*H*-pyran-4(3*H*)-one [**3aa**]

The compound **3aa** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 4-bromobenzenediazonium tetrafluoroborate **2aa** (152 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 1.5 h. Column chromatography purification was performed using 20 % ethyl acetate in hexane which furnished **3aa** as white foam (147 mg, 90%); TLC *R_f* = 0.35 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.40 (d, *J* = 8.5 Hz, 2H), 7.18 (d, *J* = 8.0 Hz, 2H), 5.34-5.32 (m, 1H), 3.88 (d, *J* = 8.0 Hz, 1H), 3.54-3.49 (m, 3H), 3.42 (s, 3H), 3.35 (s, 3H), 2.99-2.92 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 206.1, 137.4, 131.8, 129.1, 122.3, 81.6, 74.6, 74.6, 71.5, 59.4, 59.4, 43.6. HRMS (ESI-TOF) (*m/z*): [*M* + *H*]⁺ calcd for C₁₄H₁₈BrO₄ 329.0388; found, 329.0359.

(2R,3R,6S)-6-(2-Chlorophenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3ab]

The compound **3ab** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 2-chlorobenzenediazonium tetrafluoroborate **2ab** (127 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.6 mg, 0.025 mmol) at room temperature for 1.5 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3ab** as colourless semi solid (126 mg, 89%); TLC R_f = 0.40 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.41-7.39 (m, 1H), 7.31-7.29 (m, 1H), 7.20-7.16 (m, 2H), 5.64 (t, *J* = 5.5 Hz, 1H), 3.87 (d, *J* = 7.0 Hz, 1H), 3.77-3.74 (m, 1H), 3.57-3.51 (m, 2H), 3.43 (s, 3H), 3.32 (s, 3H), 2.91 (dd, *J* = 15.0, 5.5 Hz, 1H), 2.78 (dd, *J* = 15.0, 6.0 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 206.4, 136.9, 133.3, 129.9, 129.4, 128.2, 126.8, 81.4, 75.5, 71.9, 71.9, 59.3, 59.0, 44.3. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₄H₁₈ClO₄ 285.0894; found, 285.0868.

(2R,3R,6S)-3-Methoxy-2-(methoxymethyl)-6-phenyldihydro-2H-pyran-4(3H)-one [3ac]

The compound **3ac** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (97 mg, 0.5 mmol) and benzenediazonium tetrafluoroborate **2ac** (108 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.8 mg, 0.025 mmol) at room temperature for 2 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3ac** as white foam (107 mg, 85%); TLC R_f = 0.5 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.31-7.25 (m, 4H), 7.22-7.19 (m, 1H), 5.39-5.38 (m, 1H), 3.89 (d, *J* = 8.0 Hz, 1H), 3.54-3.49 (m, 3H), 3.43 (d, *J* = 2.0 Hz, 3H), 3.35 (d, *J* = 2.0 Hz, 3H), 3.05-2.93 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 206.4, 138.3, 128.6, 128.0, 127.3, 81.6, 75.1, 74.2, 71.4, 59.4, 59.3, 43.6. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₄H₁₉O₄ 251.1283; found, 251.1265.

(2R,3R,6S)-3-Methoxy-2-(methoxymethyl)-6-(naphthalen-1-yl)dihydro-2H-pyran-4(3H)-one [3ad]

The compound **3ad** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 1-naphthylidiazonium tetrafluoroborate **2ad** (135 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.7 mg, 0.025 mmol) at room temperature for 2 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3ad** as white foam (131 mg, 87%); TLC R_f = 0.48 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 8.31 (d, *J* = 8.0 Hz, 1H), 7.77-7.71 (m, 2H), 7.49 – 7.27 (m, 4H), 6.03-6.02 (m, 1H), 4.01 (d, *J* = 9.0 Hz, 1H), 3.46 (s, 3H), 3.40-3.38 (m, 1H), 3.32-3.30 (m, 5H), 3.18-3.11 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 207.6, 133.9, 133.5, 131.5, 129.5, 128.5, 126.3, 126.2, 125.9, 124.8, 124.7, 81.5, 73.8, 72.8, 71.1, 59.7, 59.3, 44.1. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₈H₂₁O₄ 301.1440; found, 301.1437.

(2R,3R,6S)-3-Methoxy-2-(methoxymethyl)-6-p-tolyldihydro-2H-pyran-4(3H)-one [3ae] The compound **3ae** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 4-methylbenzenediazonium tetrafluoroborate **2ae** (115 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 2h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3ae** as white foam (116 mg, 87%); TLC R_f = 0.4 (15 % ethyl acetate in chloroform); ¹H NMR (500 MHz, CDCl₃) δ 7.18 (d, *J* = 7.8 Hz, 2H), 7.06 (d, *J* = 8.0 Hz, 2H), 5.36 (d, *J* = 6.0 Hz, 1H), 3.88 (d, *J* = 9.5 Hz, 1H), 3.52-3.46 (m, 3H), 3.42 (s, 3H), 3.34 (s, 3H), 3.02-2.93 (m, 2H), 2.24 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 206.7, 137.9, 135.2, 129.2, 127.4, 81.6, 75.0, 73.9, 71.4, 59.5, 59.3, 43.7, 20.9. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₅H₂₁O₄ 265.1440; found, 265.1417.

(2R,3R,6S)-3-Methoxy-2-(methoxymethyl)-6-(4-methoxyphenyl)dihydro-2H-pyran-4(3H)-one [3af]

The compound **3af** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 4-methoxybenzenediazonium tetrafluoroborate **2af** (124 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 2 h. Column chromatography purification was performed using 20 % ethyl acetate in

hexane which furnished **3af** as white foam (118 mg, 84%); TLC R_f = 0.28 (35 % ethyl acetate in hexane); ^1H NMR (500 MHz, CDCl_3) δ 7.21 (d, J = 8.0 Hz, 2H), 6.79-6.77 (m, 2H), 5.35 (dd, J = 6.5, 2.5 Hz, 1H), 3.89-3.87 (m, 1H), 3.70 (s, 3H), 3.53-3.47 (m, 3H), 3.43 (s, 3H), 3.34 (s, 3H), 3.01-2.93 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 206.8, 159.3, 130.3, 128.8, 113.9, 81.7, 74.8, 73.8, 71.4, 59.5, 59.3, 55.1, 43.7. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{21}\text{O}_5$ 281.1389; found, 281.1370

(2R,3R,6S)-3-Methoxy-2-(methoxymethyl)-6-(4-nitrophenyl) dihydro-2H-pyran-4(3H)-one [3ag]

The compound **3ag** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 4-nitrobenzenediazonium tetrafluoroborate **2ag** (132 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of $\text{Pd}(\text{OAc})_2$ (5.5 mg, 0.025 mmol) at room temperature for 4h. Column chromatography purification was performed using 25 % ethyl acetate in hexane which furnished **3ag** as white foam (98 mg, 69%); TLC R_f = 0.25 (35 % ethyl acetate in hexane); ^1H NMR (500 MHz, CDCl_3) δ 8.13 (d, J = 8.0 Hz, 2H), 7.51 (d, J = 8.0 Hz, 2H), 5.44 (t, J = 4.5 Hz, 1H), 3.88 (d, J = 7.5 Hz, 1H), 3.61-3.57 (m, 3H), 3.41 (s, 3H), 3.35 (s, 3H), 3.02-2.94 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 205.0, 147.5, 145.9, 127.9, 123.8, 81.4, 75.7, 74.4, 71.7, 59.3, 59.2, 43.7. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{18}\text{NO}_6$ 296.1134; found, 296.1108.

(2R,3R,6S)-3-Methoxy-2-(methoxymethyl)-6-(4-(trifluoromethyl)phenyl) dihydro-2H-pyran-4(3H)-one [3ah]

The compound **3ah** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 4-(trifluoromethyl)benzenediazonium tetrafluoroborate **2ah** (145 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of $\text{Pd}(\text{OAc})_2$ (5.5 mg, 0.025 mmol) at room temperature for 2 h. Column chromatography purification was performed using 20 % ethyl acetate in hexane which furnished **3ah** as viscous oil (127 mg, 79%); TLC R_f = 0.30 (35 % ethyl acetate in hexane); ^1H NMR (500 MHz, CDCl_3) δ 7.53 (d, J = 7.5 Hz, 2H), 7.44 (d, J = 7.5 Hz, 2H), 5.41 (m, 1H), 3.88 (d, J = 7.0 Hz, 1H), 3.54 (m, 3H), 3.41 (s, 3H), 3.35 (s, 3H), 3.03-2.94 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 205.6, 142.5, 130.4 (q, $J_{\text{C-F}}$ = 32.5 Hz), 127.5, 126.7 (q, $J_{\text{C-F}}$ = 3.8 Hz), 123.8 (q, $J_{\text{C-F}}$ = 272 Hz), 81.5, 75.2, 74.6, 71.6, 59.3, 59.3, 43.7. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{18}\text{F}_3\text{O}_4$ 319.1157; found, 319.1139.

Methyl 4-((2S,5R,6R)-5-methoxy-6-(methoxymethyl)-4-oxotetrahydro-2H-pyran-2-yl)benzoate [3ai]

The compound **3ai** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 4-(methoxycarbonyl)benzenediazonium tetrafluoroborate **2ai** (140 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 2 h. Column chromatography purification was performed using 20 % ethyl acetate in hexane which furnished **3ai** as white foam (118 mg, 76%); TLC R_f = 0.24 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.94 (d, *J* = 8.0 Hz, 2H), 7.39 (d, *J* = 8.0 Hz, 2H), 5.41 (dd, *J* = 6.0, 3.5 Hz, 1H), 3.88 (d, *J* = 7.5 Hz, 1H), 3.84 (s, 3H), 3.53 (m, 3H), 3.41 (s, 3H), 3.35 (s, 3H), 3.04-2.94 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 205.9, 166.6, 143.5, 130.0, 129.9, 127.2, 81.6, 75.0, 74.9, 71.6, 59.4, 52.2, 43.7. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₆H₂₁O₆ 309.1338; found, 309.1339.

(2R,3R,6S)-6-(4-Acetylphenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3aj]

The compound **3aj** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 4-acetylbenzenediazonium tetrafluoroborate **2aj** (130 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 3h. Column chromatography purification was performed using 20 % ethyl acetate in hexane which furnished **3aj** as yellowish foam (115 mg, 78%); TLC R_f = 0.40 (15 % ethyl acetate in chloroform); ¹H NMR (500 MHz, CDCl₃) δ 7.86 (d, *J* = 8.0 Hz, 2H), 7.41 (d, *J* = 8.0 Hz, 2H), 5.41 (m, 1H), 3.88 (d, *J* = 8.0 Hz, 1H), 3.53 (s, 3H), 3.41 (s, 3H), 3.35 (s, 3H), 3.04-3.94 (m, 2H), 2.51 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 205.7, 197.4, 143.6, 136.6, 128.6, 127.3, 81.5, 75.0, 74.7, 71.5, 59.3, 59.3, 43.6, 26.5. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₆H₂₁O₅ 293.1389; found, 293.1393.

4-((2S,5R,6R)-5-Methoxy-6-(methoxymethyl)-4-oxotetrahydro-2H-pyran-2-yl)benzonitrile [3ak]

The compound **3ak** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 4-cyanobenzenediazonium tetrafluoroborate **2ak** (121 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂

(5.5 mg, 0.025 mmol) at room temperature for 2.5 h. Column chromatography purification was performed using 20 % ethyl acetate in hexane which furnished **3ak** as white foam (111 mg, 80%); TLC R_f = 0.26 (35 % ethyl acetate in hexane); ^1H NMR (500 MHz, CDCl_3) δ 7.58 (d, J = 8.0 Hz, 2H), 7.44 (d, J = 8.0 Hz, 2H), 5.40 (t, J = 5.0 Hz, 1H), 3.87 (d, J = 7.0 Hz, 1H), 3.59-3.55 (m, 3H), 3.41 (s, 3H), 3.35 (s, 3H), 3.00-2.93 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 205.3, 143.9, 132.5, 127.8, 118.3, 112.0, 81.4, 75.5, 74.6, 71.7, 59.4, 59.3, 43.6. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{18}\text{NO}_4$ 276.1236; found, 276.1229.

(2R,3R,6S)-6-(4-Fluorophenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3al]

The compound **3al** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 4-fluorobenzenediazonium tetrafluoroborate **2al** (116 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of $\text{Pd}(\text{OAc})_2$ (5.5 mg, 0.025 mmol) at room temperature for 2 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3al** as white foam (114 mg, 84%); TLC R_f = 0.42 (35 % ethyl acetate in hexane); ^1H NMR (500 MHz, CDCl_3) δ 7.32 (t, J = 7.0 Hz, 2H), 6.99 (t, J = 8.0 Hz, 2H), 5.40 (m, 1H), 3.93 (d, J = 8.5 Hz, 1H), 3.58-3.50 (m, 3H), 3.47 (s, 3H), 3.39 (s, 3H), 3.07-2.98 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 206.3, 162.4 (d, $J_{\text{C-F}}$ = 247.5 Hz), 134.2 (d, $J_{\text{C-F}}$ = 3.3 Hz), 129.3 (d, $J_{\text{C-F}}$ = 8.2 Hz), 116.0 (d, $J_{\text{C-F}}$ = 21.5 Hz), 81.6, 74.6, 74.4, 71.5, 59.5, 59.4, 43.8. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{14}\text{H}_{17}\text{FO}_4\text{Na}$ 291.1009; found, 291.0985.

(2R,3R,6S)-6-(4-Chlorophenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3am]

The compound **3am** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 4-chlorobenzenediazonium tetrafluoroborate **2am** (126 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of $\text{Pd}(\text{OAc})_2$ (5.5 mg, 0.025 mmol) at room temperature for 2 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3am** as white foam (123 mg, 85%); TLC R_f = 0.42 (35 % ethyl acetate in hexane); ^1H NMR (500 MHz, CDCl_3) δ 7.33 (s, 4H), 5.44-5.43 (m, 1H), 3.96 (d, J = 8.0 Hz, 1H), 3.62-3.55 (m, 3H), 3.51 (s, 3H), 3.43 (s, 3H), 3.08-3.01 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ

206.1, 136.9, 134.1, 128.8, 128.8, 81.6, 74.6, 74.6, 71.5, 59.5, 59.4, 43.7. HRMS (ESI-TOF) (m/z): [M + H]⁺ calcd for C₁₄H₁₈ClO₄ 285.0894; found, 285.0870.

(2R,3R,6S)-6-(4-Iodophenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3an]

The compound **3an** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 4-iodobenzenediazonium tetrafluoroborate **2an** (177 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 2h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3an** as brownish foam (170 mg, 90%); TLC R_f = 0.63 (15 % ethyl acetate in chloroform); ¹H NMR (500 MHz, CDCl₃) δ 7.60 (d, *J* = 7.5 Hz, 2H), 7.04 (d, *J* = 8.0 Hz, 2H), 5.31 (m, 1H), 3.86 (d, *J* = 8.5 Hz, 1H), 3.56-3.51 (m, 3H), 3.41 (s, 3H), 3.34 (s, 3H), 2.97-2.90 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 205.9, 138.1, 137.7, 129.2, 94.0, 81.5, 74.7, 74.6, 71.5, 59.4, 59.3, 43.5. HRMS (ESI-TOF) (m/z): [M + H]⁺ calcd for C₁₄H₁₈IO₄ 377.0250; found, 377.0250.

(2R,3R,6S)-6-(2-Ethylphenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3ao]

The compound **3ao** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 2-ethylbenzenediazonium tetrafluoroborate **2ao** (123 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 2 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3ao** as semi solid (106 mg, 76%); TLC R_f = 0.47 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.20-7.17 (m, 3H), 7.07-7.04 (m, 1H), 5.59 (t, *J* = 4.5 Hz, 1H), 3.93 (d, *J* = 9.0 Hz, 1H), 3.50-3.41 (m, 6H), 3.32 (s, 3H), 2.94 (d, *J* = 4.5 Hz, 2H), 2.80-2.67 (m, 2H), 1.16 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 207.7, 143.6, 135.8, 129.2, 128.7, 127.6, 125.7, 81.6, 73.9, 72.3, 71.6, 59.6, 59.4, 44.4, 25.1, 15.41. HRMS (ESI-TOF) (m/z): [M + H]⁺ calcd for C₁₆H₂₃O₄ 279.1596; found, 279.1575.

(2R,3R,6S)-6-(2,4-Dimethylphenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3ap]

The compound **3ap** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 2,4-dimethylbenzenediazonium tetrafluoroborate **2ap** (123 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 2 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3ap** as white foam (100 mg, 71%); TLC R_f = 0.48 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.04 (d, *J* = 8.0 Hz, 1H), 6.94 (s, 1H), 6.85 (d, *J* = 7.5 Hz, 1H), 5.48 (t, *J* = 4.5 Hz, 1H), 3.91 (d, *J* = 9.0 Hz, 1H), 3.49-3.37 (m, 6H), 3.33 (s, 3H), 2.99-2.93 (m, 2H), 2.32 (s, 3H), 2.20 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 207.7, 138.2, 137.7, 133.3, 131.9, 127.6, 126.2, 81.6, 73.4, 72.8, 71.4, 59.6, 59.3, 44.0, 20.9, 19.4. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₆H₂₃O₄ 279.1596; found, 279.1575.

(2R,3R,6S)-6-(2,5-Dimethylphenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3aq]

The compound **3aq** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 2,5-dimethylbenzenediazonium tetrafluoroborate **2aq** (122 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 4 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3aq** as semi solid (113 mg, 81%); TLC R_f = 0.65 (15 % ethyl acetate in chloroform); ¹H NMR (500 MHz, CDCl₃) δ 7.00-6.99 (m, 2H), 6.94-6.93 (m, 1H), 5.48-5.47 (m, 1H), 3.91 (d, *J* = 9.0 Hz, 1H), 3.51-3.42 (m, 6H), 3.33 (s, 3H), 2.99-2.90 (m, 2H), 2.30 (s, 3H), 2.20 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 207.4, 136.3, 135.2, 134.4, 130.9, 129.0, 128.1, 81.8, 73.8, 72.9, 71.6, 59.6, 59.3, 44.0, 21.0, 19.1. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₆H₂₃O₄ 279.1596; found, 279.1596.

(2R,3R,6S)-6-(3-Fluorophenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3ar]

The compound **3ar** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 3-fluorobenzenediazonium tetrafluoroborate **2ar** (117 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂

(5.5 mg, 0.025 mmol) at room temperature for 3 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3ar** as brownish semi solid (112 mg, 83%); TLC R_f = 0.6 (15 % ethyl acetate in chloroform); ^1H NMR (500 MHz, CDCl_3) δ 7.25-7.21 (m, 1H), 7.06 (t, J = 8.5 Hz, 2H), 6.90 (t, J = 8.5 Hz, 1H), 5.35 (m, 1H), 3.88 (d, J = 7.5 Hz, 1H), 3.55-3.54 (m, 3H), 3.42 (s, 3H), 3.35 (s, 3H), 3.00-2.92 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 205.8, 162.9 (d, $J_{\text{C-F}}$ = 247.0 Hz), 141.11 (d, $J_{\text{C-F}}$ = 6.7 Hz), 130.2 (d, $J_{\text{C-F}}$ = 8.2 Hz), 122.7 (d, $J_{\text{C-F}}$ = 2.8 Hz), 115.1 (d, $J_{\text{C-F}}$ = 22.1 Hz), 114.4 (d, $J_{\text{C-F}}$ = 22.1 Hz), 81.5, 74.8, 74.6, 71.5, 59.3, 59.3, 43.6. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{18}\text{FO}_4$ 269.1189; found, 269.1199.

(2R,3R,6S)-6-(3-Chlorophenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3as]

The compound **3as** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 3-chlorobenzenediazonium tetrafluoroborate **2as** (125 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of $\text{Pd}(\text{OAc})_2$ (5.5 mg, 0.025 mmol) at room temperature for 3 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3as** as viscous oil (122 mg, 85%); TLC R_f = 0.46 (35 % ethyl acetate in hexane); ^1H NMR (500 MHz, CDCl_3) δ 7.20-7.16 (m, 3H), 5.33 (dd, J = 6.0, 3.5 Hz, 1H), 3.88 (d, J = 8.0 Hz, 1H), 3.58-3.54 (m, 3H), 3.42 (s, 3H), 3.35 (s, 3H), 2.99-2.90 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 205.7, 140.7, 134.8, 129.9, 128.3, 127.5, 125.2, 81.5, 74.9, 74.6, 71.6, 59.3, 43.7. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{18}\text{ClO}_4$ 285.0894; found, 285.0876.

(2R,3R,6S)-6-(3-Bromophenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3at]

The compound **3at** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 3-bromobenzenediazonium tetrafluoroborate **2at** (152 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of $\text{Pd}(\text{OAc})_2$ (5.5 mg, 0.025 mmol) at room temperature for 2.5 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3at** as brownish oil (138 mg, 83%); TLC R_f = 0.64 (15 % ethyl acetate in chloroform); ^1H NMR (500 MHz, CDCl_3) δ 7.48 (s, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.21 (m, J = 7.5 Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 5.32 (m, 1H), 3.87 (d, J = 8.0 Hz, 1H), 3.58-3.54 (m, 3H), 3.41

(s, 3H), 3.35 (s, 3H), 2.98-2.89 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 205.6, 140.9, 131.2, 130.3, 130.1, 125.6, 122.9, 81.5, 74.9, 74.5, 71.5, 59.3, 43.6. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{18}\text{BrO}_4$ 329.0388; found, 329.0393.

(2R,3R,6S)-6-(3,5-Dichlorophenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3au]

The compound **3au** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 3,5-dichlorobenzenediazonium tetrafluoroborate **2au** (145 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of $\text{Pd}(\text{OAc})_2$ (5.5 mg, 0.025 mmol) at room temperature for 4 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3au** as colourless oil (105 mg, 65%); TLC R_f = 0.64 (15 % ethyl acetate in chloroform); ^1H NMR (500 MHz, CDCl_3) δ 7.20 (m, 3H), 5.28 (m, 1H), 3.86 (d, J = 7.5 Hz, 1H), 3.64-3.63 (m, 1H), 3.56 (s, 2H), 3.41 (s, 3H), 3.35 (s, 3H), 2.93-2.86 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 205.0, 142.3, 135.4, 128.3, 125.5, 81.4, 75.5, 74.1, 71.7, 59.4, 59.2, 43.7. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{17}\text{Cl}_2\text{O}_4$ 319.0504; found, 319.0506.

(2R,3R,6S)-6-(4-Bromo-3-methylphenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3av]

The compound **3av** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 4-bromo-3-methylbenzenediazonium tetrafluoroborate **2av** (160 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of $\text{Pd}(\text{OAc})_2$ (5.5 mg, 0.025 mmol) at room temperature for 2 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3av** as brownish oil (145 mg, 84%); TLC R_f = 0.3 (15 % ethyl acetate in chloroform); ^1H NMR (500 MHz, CDCl_3) δ 7.40 (d, J = 8.0 Hz, 1H), 7.16 (s, 1H), 6.97 (d, J = 8.0 Hz, 1H), 5.29 (m, 1H), 3.86 (d, J = 7.5 Hz, 1H), 3.54-3.49 (m, 3H), 3.41 (s, 3H), 3.34 (s, 3H), 2.97-2.89 (m, 2H), 2.29 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 206.0, 138.1, 137.7, 132.4, 129.6, 126.2, 124.6, 81.5, 74.5, 74.5, 71.5, 59.3, 59.2, 43.6, 22.8. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{20}\text{BrO}_4$ 343.0545; found, 343.0547.

(2R,3R,6S)-6-(3-Acetylphenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3aw]

The compound **3aw** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 3-acetylbenzenediazonium tetrafluoroborate **2aw** (130 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 2 h. Column chromatography purification was performed using 20 % ethyl acetate in hexane which furnished **3aw** as colourless oil (131 mg, 89%); TLC R_f = 0.3 (15 % ethyl acetate in chloroform); ¹H NMR (500 MHz, CDCl₃) δ 7.91 (s, 1H), 7.81 (d, *J* = 7.0 Hz, 1H), 7.51 (d, *J* = 7.5 Hz, 1H), 7.38 (t, *J* = 7.5 Hz, 1H), 5.42 (m, 1H), 3.88 (d, *J* = 8.0 Hz, 1H), 3.57-3.54 (m, 3H), 3.41 (s, 3H), 3.35 (s, 3H), 3.06-2.95 (m, 2H), 2.53 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 205.7, 197.7, 139.2, 137.5, 131.5, 129.0, 127.9, 127.2, 81.6, 75.0, 74.8, 71.6, 59.3, 59.3, 43.8, 26.6. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₆H₂₁O₅ 293.1389; found, 293.1391.

(2R,3R,6S)-3-Methoxy-2-(methoxymethyl)-6-(3-nitrophenyl)dihydro-2H-pyran-4(3H)-one [3ax]

The compound **3ax** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 3-nitrobenzenediazonium tetrafluoroborate **2ax** (132 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 4h. Column chromatography purification was performed using 25 % ethyl acetate in hexane which furnished **3ax** as yellowish oil (103 mg, 69%); TLC R_f = 0.30 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 8.22 (s, 1H), 8.09 (d, *J* = 8.5 Hz, 1H), 7.65 (d, *J* = 7.5 Hz, 1H), 7.48 (t, *J* = 8.0 Hz, 1H), 5.45 (t, *J* = 5.0 Hz, 1H), 3.89 (d, *J* = 7.5 Hz, 1H), 3.65-3.55 (m, 3H), 3.41 (s, 3H), 3.36 (s, 3H), 3.04-2.95 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 205.0, 148.5, 141.1, 132.8, 129.7, 123.0, 122.1, 81.4, 75.7, 74.3, 71.8, 59.4, 59.2, 43.9. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₄H₁₈NO₆ 296.1134; found, 296.1068.

(2R,3R,6S)-3-Methoxy-2-(methoxymethyl)-6-(3-(trifluoromethyl)phenyl)dihydro-2H-pyran-4(3H)-one [3ay]

The compound **3ay** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 3-(trifluoromethyl)benzenediazonium tetrafluoroborate **2ay** (144 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of

Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 2 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3ay** as colourless oil (135 mg, 84%); TLC R_f = 0.6 (15 % ethyl acetate in chloroform); ¹H NMR (500 MHz, CDCl₃) δ 7.60 (s, 1H), 7.49-7.47 (m, 2H), 7.40 (t, *J* = 7.5 Hz, 1H), 5.41-5.39 (m, 1H), 3.87 (d, *J* = 8.0 Hz, 1H), 3.62-3.59 (m, 1H), 3.56-3.55 (m, 2H), 3.41 (s, 3H), 3.35 (s, 3H), 3.03-2.92 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 205.4, 139.8, 131.3 (q, *J*_{C-F} = 32.4 Hz), 129.1, 124.9 (q, *J*_{C-F} = 3.7 Hz), 124.0 (q, *J*_{C-F} = 3.7 Hz), 123.8 (q, *J*_{C-F} = 272 Hz), 81.5, 75.3, 74.7, 71.7, 59.3, 59.2, 43.8. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₅H₁₈F₃O₄ 319.1157; found, 319.1160.

(2R,3R,6S)-6-(3,5-Dimethylphenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3az]

The compound **3az** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 3,5-dimethylbenzenediazonium tetrafluoroborate **2az** (122 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 3.5 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3az** as colourless solid (86 mg, 61%); TLC R_f = 0.42 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 6.90-6.83 (m, 3H), 5.30-5.29 (m, 1H), 3.87 (d, *J* = 8.5 Hz, 1H), 3.57-3.49 (m, 3H), 3.43 (s, 3H), 3.34 (s, 3H), 3.01-2.98 (m, 1H), 2.90-2.88 (m, 1H), 2.21 (s, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 206.5, 138.4, 138.1, 129.7, 125.1, 81.7, 75.1, 74.2, 71.5, 59.4, 59.2, 43.7, 21.2. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₆H₂₃O₄ 279.1596; found, 279.1595.

(2R,3R,6S)-3-(Benzyloxy)-2-(benzyloxymethyl)-6-phenyldihydro-2H-pyran-4(3H)-one [3ba]

The compound **3ba** was prepared using the general procedure. The reaction was carried out between tri-*O*-benzyl-D-glucal **1ab** (100 mg, 0.24 mmol) and benzenediazonium tetrafluoroborate **2ac** (52 mg, 0.27 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 5 h. Column chromatography purification was performed using 10 % ethyl acetate in hexane which furnished **3ba** as white foam (77 mg, 80%); TLC R_f = 0.28 (20 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.30 (d, *J* = 7.5 Hz, 2H), 7.26-7.19 (m, 13H), 5.40-5.39 (m, 1H), 4.76 (d, *J* = 11.5 Hz, 1H), 4.50 (d, *J* = 12.0 Hz, 1H), 4.39 (d, *J* = 12.0 Hz, 1H), 4.34 (d, *J* = 11.0 Hz,

1H), 4.17 (d, J = 8.5 Hz, 1H), 3.65-3.56 (m, 3H), 3.05-2.93 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 206.4, 138.5, 137.7, 137.3, 128.6, 128.3, 128.3, 128.1, 128.1, 127.8, 127.8, 127.7, 127.3, 79.5, 75.1, 74.5, 73.5, 73.3, 69.0, 43.8. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{27}\text{O}_4$ 403.1909; found, 403.1916.

(2R,3R,6S)-3-(Benzyloxy)-2-(benzyloxymethyl)-6-p-tolyldihydro-2H-pyran-4(3H)-one [3bb]

The compound **3bb** was prepared using the general procedure. The reaction was carried out between tri-*O*-benzyl-D-glucal **1ab** (100 mg, 0.24 mmol) and 4-methylbenzenediazonium tetrafluoroborate **2ae** (55 mg, 0.27 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of $\text{Pd}(\text{OAc})_2$ (5.5 mg, 0.025 mmol) at room temperature for 4h. Column chromatography purification was performed using 10 % ethyl acetate in hexane which furnished **3bb** as white foam (89 mg, 89%); TLC R_f = 0.65 (30 % ethyl acetate in hexane); ^1H NMR (500 MHz, CDCl_3) δ 7.25-7.18 (m, 12H), 7.06 (d, J = 7.5 Hz, 2H), 5.39-5.37 (m, 1H), 4.77 (d, J = 11.0 Hz, 1H), 4.52 (d, J = 12.0 Hz, 1H), 4.40 (d, J = 12.0 Hz, 1H), 4.34 (d, J = 11.0 Hz, 1H), 4.16 (d, J = 8.5 Hz, 1H), 3.63-3.57 (m, 3H), 3.04-2.94 (m, 2H), 2.23 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 206.6, 137.9, 137.8, 137.3, 135.4, 129.3, 128.3, 128.33, 128.1, 127.8, 127.8, 127.7, 127.4, 79.6, 75.0, 74.3, 73.5, 73.4, 69.0, 43.9, 21.0. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{29}\text{O}_4$ 417.2066; found, 417.2070.

(2R,3R,6S)-3-(Benzyloxy)-2-(benzyloxymethyl)-6-(4-methoxyphenyl)dihydro-2H-pyran-4(3H)-one [3bc]

The compound **3bc** was prepared using the general procedure. The reaction was carried out between tri-*O*-benzyl-D-glucal **1ab** (100 mg, 0.24 mmol) and 4-methoxybenzenediazonium tetrafluoroborate **2af** (60 mg, 0.27 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of $\text{Pd}(\text{OAc})_2$ (5.5 mg, 0.025 mmol) at room temperature for 4 h. Column chromatography purification was performed using 12 % ethyl acetate in hexane which furnished **3bc** as white foam (88 mg, 85%); TLC R_f = 0.25 (15 % ethyl acetate in hexane); ^1H NMR (500 MHz, CDCl_3) δ 7.26-7.18 (m, 12H), 6.77 (d, J = 8.5 Hz, 2H), 5.37 (dd, J = 6.5, 2.5 Hz, 1H), 4.77 (d, J = 11 Hz, 1H), 4.51 (d, J = 12. Hz, 1H), 4.39 (d, J = 12. Hz, 1H), 4.34 (d, J = 11. Hz, 1H), 4.16 (d, J = 9 Hz, 1H), 3.69 (s, 3H), 3.62-3.54 (m, 3H), 3.03-2.94 (m Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 206.7, 159.3,

137.8, 137.3, 130.5, 128.8, 128.3, 128.3, 128.1, 127.8, 127.8, 127.7, 113.9, 79.6, 74.8, 74.0, 73.5, 73.4, 68.9, 55.2, 43.9. HRMS (ESI-TOF) (m/z): [M + H]⁺ calcd for C₁₄H₁₈BrO₄ 433.2015; found, 433.2000.

(2R,3R,6S)-3-(Benzyloxy)-2-(benzyloxymethyl)-6-(4-fluorophenyl)dihydro-2H-pyran-4(3H)-one [3bd]

The compound **3bd** was prepared using the general procedure. The reaction was carried out between tri-*O*-benzyl-D-glucal **1ab** (100 mg, 0.24 mmol) and 4-fluorobenzenediazonium tetrafluoroborate **2al** (56 mg, 0.27 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 4 h. Column chromatography purification was performed using 8 % ethyl acetate in hexane which furnished **3bd** as white foam (85 mg, 84%); TLC R_f = 0.62 (30 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.29-7.17 (m, 12H), 6.93 (t, *J* = 8.0 Hz, 2H), 5.37 (m, 1H), 4.75 (d, *J* = 11.5 Hz, 1H), 4.50 (d, *J* = 12.0 Hz, 1H), 4.40 (d, *J* = 12.0 Hz, 1H), 4.34 (d, *J* = 11.0 Hz, 1H), 4.15 (d, *J* = 8.0 Hz, 1H), 3.62-3.55 (m, 3H), 3.01-2.93 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 206.2, 162.4 (d, *J*_{C-F} = 247.5 Hz), 137.7, 137.2, 134.2 (d, *J*_{C-F} = 3.3 Hz), 129.3 (d, *J*_{C-F} = 8.2 Hz), 128.3, 128.3, 128.1, 127.9, 127.8, 127.7, 115.5 (d, *J*_{C-F} = 21.5 Hz), 79.4, 74.6, 74.6, 73.5, 73.3, 69.0, 44.0. HRMS (ESI-TOF) (m/z): [M + H]⁺ calcd for C₂₆H₂₆FO₄ 421.1815; found, 421.1813.

(2R,3R,6S)-3-(Benzyloxy)-2-(benzyloxymethyl)-6-(4-chlorophenyl)dihydro-2H-pyran-4(3H)-one [3be]

The compound **3be** was prepared using the general procedure. The reaction was carried out between tri-*O*-benzyl-D-glucal **1ab** (100 mg, 0.24 mmol) and 4-chlorobenzenediazonium tetrafluoroborate **2am** (60 mg, 0.27 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 4 h. Column chromatography purification was performed using 8 % ethyl acetate in hexane which furnished **3be** as white foam (89 mg, 85%); TLC R_f = 0.4 (15 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.25-7.17 (m, 14H), 5.36 (m, 1H), 4.75 (d, *J* = 11.0 Hz, 1H), 4.50 (d, *J* = 12.0 Hz, 1H), 4.40 (d, *J* = 12.0 Hz, 1H), 4.33 (d, *J* = 11.0 Hz, 1H), 4.15 (d, *J* = 8.5 Hz, 1H), 3.62-3.56 (m, 3H), 3.00-2.92 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 206.0, 137.7, 137.2, 137.1, 134.1, 128.8, 128.7, 128.3, 128.3, 128.1, 127.9, 127.8, 127.7, 79.4, 74.8, 74.5, 73.5, 73.3, 69.0, 43.9. HRMS (ESI-TOF) (m/z): [M + H]⁺ calcd for C₂₆H₂₆ClO₄ 437.1520; found, 437.1521.

(2R,3R,6S)-3-(Benzyloxy)-2-(benzyloxymethyl)-6-(4-bromophenyl) dihydro-2H-pyran-4(3H)-one [3bf]

The compound **3bf** was prepared using the general procedure. The reaction was carried out between tri-*O*-benzyl-D-glucal **1ab** (100 mg, 0.24 mmol) and 4-bromobenzenediazonium tetrafluoroborate **2aa** (72 mg, 0.27 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 4 h. Column chromatography purification was performed using 10 % ethyl acetate in hexane which furnished **3bf** as white foam (94 mg, 82%); TLC R_f = 0.29 (15 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.38 (d, *J* = 7.5 Hz, 2H), 7.31-7.13 (m, 12H), 5.34 (m, 1H), 4.74 (d, *J* = 11.5 Hz, 1H), 4.50 (d, *J* = 12.5 Hz, 1H), 4.39 (d, *J* = 12.5 Hz, 1H), 4.33 (d, *J* = 11.0 Hz, 1H), 4.14 (d, *J* = 8.5 Hz, 1H), 3.63-3.56 (m, 3H), 2.99-2.91 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 205.9, 137.7, 137.6, 137.1, 131.8, 129.0, 128.3, 128.3, 128.1, 127.9, 127.8, 127.7, 122.2, 79.3, 74.9, 74.6, 73.5, 73.3, 69.0, 43.8. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₂₆H₂₆BrO₄ 481.1014; found, 481.1020.

4-((2S,5R,6R)-5-(Benzyloxy)-6-(benzyloxymethyl)-4-oxotetrahydro-2H-pyran-2-yl)benzonitrile [3bg]

The compound **3bg** was prepared using the general procedure. The reaction was carried out between tri-*O*-benzyl-D-glucal **1ab** (100 mg, 0.24 mmol) and 4-cyanobenzenediazonium tetrafluoroborate **2ak** (58 mg, 0.27 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 4 h. Column chromatography purification was performed using 10 % ethyl acetate in hexane which furnished **3bg** as white foam (72 mg, 70%); TLC R_f = 0.25 (30 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.55 (d, *J* = 7.5 Hz, 2H), 7.42 (d, *J* = 7.5 Hz, 2H), 7.25-7.18 (m, 10H), 5.40 (m, 1H), 4.72 (d, *J* = 11.0 Hz, 1H), 4.49 (d, *J* = 12.5 Hz, 1H), 4.40 (d, *J* = 12.5 Hz, 1H), 4.33 (d, *J* = 11.0 Hz, 1H), 4.13 (d, *J* = 8.0 Hz, 1H), 3.67-3.66 (m, 1H), 3.61 (s, 2H), 3.00-2.92 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 205.2, 144.1, 137.5, 136.9, 132.4, 128.4, 128.3, 128.1, 128.0, 127.8, 127.7, 118.3, 112.0, 79.1, 75.7, 74.5, 73.5, 73.2, 69.1, 43.8. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₂₇H₂₆NO₄ 428.1862; found, 428.1858.

Methyl 4-((2S,5R,6R)-5-(benzyloxy)-6-(benzyloxymethyl)-4-oxotetrahydro-2H-pyran-2-yl)benzoate [3bh]

The compound **3bh** was prepared using the general procedure. The reaction was carried out between tri-*O*-benzyl-D-glucal **1ab** (100 mg, 0.24 mmol) and 4-(methoxycarbonyl)benzenediazonium tetrafluoroborate **2ai** (67 mg, 0.27 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 4 h. Column chromatography purification was performed using 10 % ethyl acetate in hexane which furnished **3bh** as white foam (83 mg, 75%); TLC R_f = 0.24 (15 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.92 (d, *J* = 7.5 Hz, 2H), 7.38 (d, *J* = 7.5 Hz, 2H), 7.26-7.17 (m, 10H), 5.41 (m, 1H), 4.74 (d, *J* = 11.5 Hz, 1H), 4.50 (d, *J* = 12.5 Hz, 1H), 4.40 (d, *J* = 12.0 Hz, 1H), 4.34 (d, *J* = 11.5 Hz, 1H), 4.15 (d, *J* = 8.0 Hz, 1H), 3.82 (s, 3H), 3.67-3.60 (m, 3H), 3.04-2.93 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 205.7, 166.5, 143.7, 137.6, 137.1, 129.9, 129.8, 128.3, 128.3, 128.1, 127.9, 127.7, 127.7, 127.1, 79.3, 75.2, 74.8, 73.5, 73.2, 69.1, 52.1, 43.9. HRMS (ESI-TOF) (*m/z*): [M + Na]⁺ calcd for C₂₈H₂₈O₆Na 483.1784; found, 483.1778.

(2R,3R,6S)-3-Ethoxy-2-(ethoxymethyl)-6-p-tolyldihydro-2H-pyran-4(3H)-one [3bi]

The compound **3bi** was prepared using the general procedure. The reaction was carried out between tri-*O*-ethyl-D-glucal **1ac** (115 mg, 0.5 mmol) and 4-methylbenzenediazonium tetrafluoroborate **2ae** (113 mg, 0.55 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.025 mmol) at room temperature for 2 h. Column chromatography purification was performed using 10 % ethyl acetate in hexane which furnished **3bi** as white foam (131 mg, 90%); TLC R_f = 0.64 (30 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.18 (d, *J* = 8.0 Hz, 2H), 7.05 (d, *J* = 7.5 Hz, 2H), 5.36 (d, *J* = 6.0 Hz, 1H), 4.03 (d, *J* = 8.5 Hz, 1H), 3.78-3.75 (m, 1H), 3.56-3.50 (m, 4H), 3.44-3.38 (m, 2H), 3.01-2.99 (m, 2H), 2.23 (s, 3H), 1.17-1.11 (m, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 206.9, 137.7, 135.4, 129.2, 127.3, 80.2, 74.9, 74.2, 69.1, 67.2, 66.9, 43.6, 20.9, 15.0, 14.9. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₇H₂₅O₄ 293.1753; found, 293.1748.

(2R,3R,6S)-3-(Methoxymethoxy)-2-((methoxymethoxy)methyl)-6-p-tolyldihydro-2H-pyran-4(3H)-one [3bj]

The compound **3bj** was prepared using the general procedure. The reaction was carried out between tri-*O*-(methoxymethyl ether)-D-glucal **1ad** (100 mg, 0.35 mmol) and 4-methylbenzenediazonium tetrafluoroborate **2ae** (82 mg, 0.4 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (8 mg, 0.035 mmol) at room temperature for 7 h. Column chromatography purification was performed using 30 % ethyl acetate in hexane which furnished **3bj** as colorless solid (75 mg, 60%); TLC R_f = 0.45 (15 % ethyl acetate in chloroform); ¹H NMR (500 MHz, CDCl₃) δ 7.20-7.18 (m, 2H), 7.08 (d, *J* = 8.0 Hz, 2H), 5.38 (d, *J* = 6.0 Hz, 1H), 4.71 (d, *J* = 6.5 Hz, 2H), 4.64-4.61 (m, 3H), 4.29 (d, *J* = 8.0 Hz, 1H), 3.70-3.65 (m, 2H), 3.61 (d, *J* = 9.0 Hz, 1H), 3.35 (s, 3H), 3.31 (s, 3H), 3.04 (d, *J* = 9.5 Hz, 2H), 2.98-2.94 (m, 2H), 2.25 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 205.8, 138.0, 135.3, 129.3, 127.3, 96.9, 96.7, 76.7, 75.0, 74.2, 66.7, 56.3, 55.5, 43.9, 21.0. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₇H₂₅O₆ 325.1651; found, 325.1661.

((2R,3R,6S)-3-Acetoxy-4-oxo-6-p-tolyltetrahydro-2H-pyran-2-yl)methyl acetate [3bk]

The reaction was carried out between 3,4,6-tri-*O*-acetyl-D-glucal **1ag** (100 mg, 0.37 mmol) and 4-methylbenzenediazonium tetrafluoroborate **2ae** (83 mg, 0.4 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.6 mg, 0.025 mmol) at room temperature for 5 h. The desired product **3bk** was not obtained.

(2R,3S,6S)-3-Methoxy-2-(methoxymethyl)-6-phenyldihydro-2H-pyran-4(3H)-one [3bl]

The compound **3bl** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-galactal **1ae** (95 mg, 0.5 mmol) and benzenediazonium tetrafluoroborate **2ac** (107 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (11 mg, 0.05 mmol) at room temperature for 4 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3bl** as colourless semi solid (76 mg, 60%); TLC R_f = 0.50 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.32-7.19 (m, 5H), 5.25 (dd, *J* = 9.5, 3.5 Hz, 1H), 4.43-4.40 (m, 1H), 3.92 (dd, *J* = 6.5, 1.0 Hz, 1H), 3.69-3.62 (m, 2H), 3.47 (s, 3H), 3.25 (s, 3H), 2.76-2.72

(m, 1H), 2.61-2.56 (m, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ 203.9, 140.4, 128.5, 127.9, 125.8, 82.1, 75.8, 74.8, 71.0, 59.3, 59.0, 47.9. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{19}\text{O}_4$ 251.1283; found, 251.1265

(2R,3S,6S)-3-Methoxy-2-(methoxymethyl)-6-(naphthalen-1-yl)dihydro-2H-pyran-4(3H)-one [3bm]

The compound **3bm** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-galactal **1ae** (95 mg, 0.5 mmol) and 1-naphthylidiazonium tetrafluoroborate **2ad** (135 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of $\text{Pd}(\text{OAc})_2$ (11 mg, 0.05 mmol) at room temperature for 2.5 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3bm** as light purple solid (88 mg, 58%); TLC R_f = 0.5 (35 % ethyl acetate in hexane); ^1H NMR (500 MHz, CDCl_3) δ 8.04 (d, J = 8.0 Hz, 1H), 7.80.-7.73 (m, 2H), 7.56 (d, J = 6.5 Hz, 1H), 7.48-7.38 (m, 3H), 6.02 (d, J = 9.0 Hz, 1H), 4.42 (s, 1H), 3.97 (d, J = 5.5 Hz, 1H), 3.77-3.66 (m, 2H), 3.50 (s, 3H), 3.28 (s, 3H), 2.98-2.95 (m, 1H), 2.78-2.74 (m, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ 204.4, 135.8, 133.8, 130.4, 128.8, 128.7, 126.3, 125.7, 125.2, 123.4, 123.2, 82.2, 75.7, 71.9, 70.9, 59.3, 59.1, 46.7. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{21}\text{O}_4$ 301.1440; found, 301.1390.

(2R,3S,6S)-3-Methoxy-2-(methoxymethyl)-6-p-tolyldihydro-2H-pyran-4(3H)-one [3bn]

The compound **3bn** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-galactal **1ae** (95 mg, 0.5 mmol) and 4-methylbenzenediazonium tetrafluoroborate **2ae** (114 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of $\text{Pd}(\text{OAc})_2$ (11 mg, 0.05 mmol) at room temperature for 3 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3bn** as colourless semi solid (86 mg, 65%); TLC R_f = 0.52 (35 % ethyl acetate in hexane); ^1H NMR (500 MHz, CDCl_3) δ 7.20-7.18 (m, 2H), 7.10 (d, J = 8.0 Hz, 2H), 5.21 (dd, J = 9.5, 3.5 Hz, 1H), 4.38 (m, 1H), 3.89 (d, J = 5.5 Hz, 3H), 3.67-3.63 (m, 2H), 3.47 (s, 3H), 3.26 (s, 3H), 2.73 (dd, J = 14.0, 3.5 Hz, 1H), 2.61-2.57 (m, 1H), 2.26 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 204.1, 137.7, 137.5, 129.2, 125.9, 82.2, 75.7, 74.8, 71.1, 59.3, 59.0, 47.75, 21.0. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{21}\text{O}_4$ 265.1440; found, 265.1436.

(2R,3S,6S)-6-(4-Fluorophenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3bo]

The compound **3bo** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-galactal **1ae** (95 mg, 0.5 mmol) and 4-fluorobenzenediazonium tetrafluoroborate **2al** (117 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (11 mg, 0.05 mmol) at room temperature for 3h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3bo** as colourless semi solid (79 mg, 59%); TLC R_f = 0.65 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.29-7.27 (m, 2H), 6.97 (t, *J* = 8.5 Hz, 2H), 5.23 (dd, *J* = 10.0, 3.5 Hz, 1H), 4.41-4.38 (m, 1H), 3.91 (d, *J* = 5.5 Hz, 1H), 3.69-3.61 (m, 2H), 3.47 (s, 3H), 3.25 (s, 3H), 2.72 (dd, *J* = 14.0, 3.5 Hz, 1H), 2.57-2.52 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 203.6, 162.4 (d, *J*_{C-F} = 247.5 Hz), 136.4 (d, *J*_{C-F} = 3.3 Hz), 127.6 (d, *J*_{C-F} = 8.2 Hz), 115.4 (d, *J*_{C-F} = 21.5 Hz), 82.1, 75.9, 74.3, 71.0, 59.3, 59.1, 47.9. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₄H₁₈FO₄ 269.1189; found, 269.1154.

(2R,3S,6S)-6-(4-Chlorophenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3bp]

The compound **3bp** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-galactal **1ae** (95 mg, 0.5 mmol) and 4-chlorobenzenediazonium tetrafluoroborate **2am** (126 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (11 mg, 0.05 mmol) at room temperature for 3 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3bp** as colourless semi solid (87 mg, 61%); TLC R_f = 0.60 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.27-7.23 (m, 4H), 5.23 (dd, *J* = 10.0, 3.5 Hz, 1H), 4.40-4.39 (m, 1H), 3.90 (d, *J* = 5.5 Hz, 1H), 3.69-3.61 (m, 2H), 3.47 (s, 3H), 3.25 (s, 3H), 2.72 (dd, *J* = 14.5, 3.5 Hz, 1H), 2.54-2.49 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 203.4, 139.1, 133.6, 128.7, 127.2, 82.0, 75.9, 74.2, 71.1, 59.3, 59.1, 47.8. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₄H₁₈ClO₄ 285.0894; found, 285.0874.

(2R,3S,6S)-6-(4-Bromophenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3bq]

The compound **3bq** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-galactal **1ae** (95 mg, 0.5 mmol) and 4-bromobenzenediazonium tetrafluoroborate **2aa** (150 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (11 mg, 0.05 mmol) at room temperature for 3 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3bq** as brownish semi solid (91 mg, 55%); TLC R_f = 0.48 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.42 (d, *J* = 7.5 Hz, 2H), 7.18 (d, *J* = 8.0 Hz, 2H), 5.22 (dd, *J* = 10.0, 3.5 Hz, 1H), 4.41 (t, *J* = 5.5 Hz, 1H), 3.90 (d, *J* = 6.5 Hz, 1H), 3.69-3.61 (m, 2H), 3.48 (s, 3H), 3.25 (s, 3H), 2.72 (dd, *J* = 14.5, 3.0 Hz, 1H), 2.53-2.48 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 203.5, 139.6, 131.6, 127.5, 121.8, 82.0, 75.9, 74.3, 71.1, 59.3, 59.2, 47.8. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₄H₁₈BrO₄ 329.0388; found, 329.0361.

(2R,3S,6S)-3-Methoxy-2-(methoxymethyl)-6-(4-nitrophenyl)dihydro-2H-pyran-4(3H)-one [3br]

The compound **3br** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-galactal **1ae** (95 mg, 0.5 mmol) and 4-nitrobenzenediazonium tetrafluoroborate **2ag** (131 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (11 mg, 0.05 mmol) at room temperature for 8 h. Column chromatography purification was performed using 20 % ethyl acetate in hexane which furnished **3br** as semi solid (72 mg, 48%); TLC R_f = 0.40 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 8.16 (d, *J* = 8.5 Hz, 2H), 7.49 (d, *J* = 8.0 Hz, 2H), 5.49 (dd, *J* = 10.5, 2.5 Hz, 1H), 4.48-4.47 (m, 1H), 3.95 (d, *J* = 6.5 Hz, 1H), 3.74-3.64 (m, 2H), 3.51 (s, 3H), 3.26 (s, 3H), 2.78-2.75 (m, 1H), 2.50-2.45 (m, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 202.6, 148.0, 147.4, 126.4, 123.8, 81.8, 76.3, 74.0, 71.3, 59.4, 59.3, 48.0. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₄H₁₈NO₆ 296.1134; found, 296.1143.

4-((2S,5S,6R)-5-Methoxy-6-(methoxymethyl)-4-oxotetrahydro-2H-pyran-2-yl) benzonitrile [3bs]

The compound **3bs** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-galactal **1ae** (95 mg, 0.5 mmol) and 4-cyanobenzenediazonium tetrafluoroborate **2ak** (120 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂

(11 mg, 0.05 mmol) at room temperature for 6 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3bs** as colourless semi solid (68 mg, 49%); TLC R_f = 0.42 (35 % ethyl acetate in hexane); ^1H NMR (500 MHz, CDCl_3) δ 7.59 (d, J = 8.0 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 5.33 (dd, J = 10.0, 3.0 Hz, 1H), 4.45 (m, 1H), 3.92 (d, J = 6.0 Hz, 1H), 3.72-3.70 (m, 1H), 3.66-3.63 (m, 1H), 3.49 (s, 3H), 3.25 (s, 3H), 2.74 (dd, J = 14.0, 3.5 Hz, 1H), 2.49-2.44 (m, 1H). ^{13}C NMR (126 MHz, CDCl_3) δ 202.8, 146.0, 132.4, 126.3, 118.5, 111.7, 81.8, 76.2, 74.1, 71.3, 59.4, 59.3, 47.8. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{18}\text{NO}_4$ 276.1236; found, 276.1223.

Methyl 4-((2S,5S,6R)-5-methoxy-6-(methoxymethyl)-4-oxotetrahydro-2H-pyran-2-yl)benzoate [3bt]

The compound **3bt** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-galactal **1ae** (95 mg, 0.5 mmol) and 4-(methoxycarbonyl)benzenediazonium tetrafluoroborate **2ai** (139 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of $\text{Pd}(\text{OAc})_2$ (11 mg, 0.05 mmol) at room temperature for 4 h. Column chromatography purification was performed using 18 % ethyl acetate in hexane which furnished **3bt** as yellowish solid (80 mg, 52%); TLC R_f = 0.45 (35 % ethyl acetate in hexane); ^1H NMR (500 MHz, CDCl_3) δ 7.96 (d, J = 8.5 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 5.32 (dd, J = 9.5, 2.5 Hz, 1H), 4.44 (m, 1H), 3.93 (d, J = 6.0 Hz, 1H), 3.84 (s, 3H), 3.71-3.63 (m, 2H), 3.49 (s, 3H), 3.26 (s, 3H), 2.75 (dd, J = 14.5, 3.0 Hz, 1H), 2.54-2.49 (m, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ 203.3, 166.6, 145.7, 129.9, 129.7, 125.6, 82.0, 76.1, 74.4, 71.2, 59.3, 59.2, 52.1, 47.9. HRMS (ESI-TOF) (m/z): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{21}\text{O}_6$ 309.1338; found, 309.1375.

(2R,3S,6S)-6-(2,4-Dimethylphenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3bu]

The compound **3bu** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-galactal **1ae** (95 mg, 0.5 mmol) and 2,4-dimethylbenzenediazonium tetrafluoroborate **2ap** (122 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of $\text{Pd}(\text{OAc})_2$ (11 mg, 0.05 mmol) at room temperature for 5 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3bu** as colourless solid (76 mg, 54%); TLC R_f = 0.40 (35 % ethyl acetate in hexane); ^1H NMR (500 MHz, CDCl_3) δ 7.25 (d, J = 7.5 Hz, 1H), 6.96 (d, J = 7.5 Hz, 1H), 6.91 (s, 1H), 5.44 (dd, J = 9.0, 3.0 Hz, 1H), 4.36-4.35 (m, 1H), 3.92 (d, J = 6.5 Hz, 1H), 3.68-3.64 (m, 2H), 3.47 (s, 3H), 3.25 (s, 3H), 2.67 (dd, J = 14.5, 3.5 Hz, 1H), 2.62-2.58 (m, 1H), 2.25 (s, 3H), 2.22 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ

204.4, 137.6, 135.3, 135.2, 131.3, 126.9, 125.5, 82.2, 75.66 71.6, 71.1, 59.2, 59.0, 46.5, 20.9, 18.9. HRMS (ESI-TOF) (m/z): [M + H]⁺ calcd for C₁₆H₂₃O₄ 279.1596; found, 279.1610.

(2R,3S,6S)-6-(2-Chlorophenyl)-3-methoxy-2-(methoxymethyl)dihydro-2H-pyran-4(3H)-one [3bv]

The compound **3av** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-galactal **1ae** (95 mg, 0.5 mmol) and 2-chlorobenzenediazonium tetrafluoroborate **2ba** (127 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (11 mg, 0.05 mmol) at room temperature for 4 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3av** as yellowish semi solid (60 mg, 43%); TLC R_f = 0.60 (15 % ethyl acetate in chloroform); ¹H NMR (500 MHz, CDCl₃) δ 7.55-7.54 (m, 1H), 7.28-7.14 (m, 3H), 5.62 (dd, *J* = 10.5, 2.5 Hz, 1H), 4.52-4.50 (m, 1H), 3.99(d, *J* = 6.0 Hz, 1H), 3.69-3.68 (m, 2H), 3.51 (s, 3H), 3.27 (s, 3H), 2.84 (dd, *J* = 14.5, 3.0 Hz, 1H), 2.40-2.34 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 203.2, 138.5, 131.8, 129.4, 128.9, 127.2, 126.8, 82.0, 76.3, 71.4, 70.9, 59.3, 59.3, 46.8. HRMS (ESI-TOF) (m/z): [M + H]⁺ calcd for C₁₄H₁₈ClO₄ 285.0894; found, 285.0890.

(2R,3S,6S)-3-Methoxy-2-(methoxymethyl)-6-(3-nitrophenyl)dihydro-2H-pyran-4(3H)-one [3bw]

The compound **3bw** was prepared using the general procedure. The reaction was carried out between tri-*O*-methyl-D-galactal **1ae** (95 mg, 0.5 mmol) and 3-nitrobenzenediazonium tetrafluoroborate **2ax** (140 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (11 mg, 0.05 mmol) at room temperature for 8 h. Column chromatography purification was performed using 20 % ethyl acetate in hexane which furnished **3bw** as yellowish semi solid (60 mg, 40%); TLC R_f = 0.3 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 8.24 (s, 1H), 8.19 (d, *J* = 7.0 Hz, 1H), 7.60 (d, *J* = 7.5 Hz, 1H), 7.47 (t, *J* = 8.0 Hz, 1H), 5.39 (dd, *J* = 10.0, 2.5 Hz, 1H), 4.49 (t, *J* = 4.5 Hz, 1H), 3.97 (d, *J* = 6.5 Hz, 1H), 3.74-3.64 (m, 2H), 3.51 (s, 3H), 3.27 (s, 3H), 2.77 (dd, *J* = 14.5, 3.5 Hz, 1H), 2.53-2.48 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 202.6, 148.4, 143.1, 131.7, 129.5, 122.8, 120.8, 81.8, 76.3, 73.9, 71.3, 59.4, 59.3, 48.1. HRMS (ESI-TOF) (m/z): [M + H]⁺ calcd for C₁₄H₁₈NO₆ 296.1134; found, 296.1115.

(2R,3S,6S)-3-(Benzyloxy)-2-(benzyloxymethyl)-6-phenyldihydro-2H-pyran-4(3H)-one [3bx]

The compound **3bx** was prepared using the general procedure. The reaction was carried out between tri-*O*-benzyl-D-galactal **1af** (100 mg, 0.24 mmol) and benzenediazonium tetrafluoroborate **2ac** (66 mg, 0.27 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.024 mmol) at room temperature for 4h. Column chromatography purification was performed using 10 % ethyl acetate in hexane which furnished **3bx** as colourless semi solid (48 mg, 50%); TLC R_f = 0.48 (15 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.28-7.17 (m, 15H), 5.25 (dd, *J* = 9.5, 2.5 Hz, 1H), 4.86 (d, *J* = 12.0 Hz, 1H), 4.51 (d, *J* = 4.5 Hz, 1H), 4.48 (d, *J* = 4.5 Hz, 1H), 4.42 (d, *J* = 12.0 Hz, 1H), 4.37 (s, 1H), 4.09 (d, *J* = 6.5 Hz, 1H), 3.78-3.71 (m, 2H), 2.73 (dd, *J* = 14.5, 3.0 Hz, 1H), 2.59-2.54 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 204.1, 140.5, 137.9, 137.4, 128.5, 128.4, 128.3, 128.0, 12.9, 127.8, 127.6, 127.5, 125.9, 79.2, 76.4, 74.7, 73.5, 72.6, 68.4, 47.9 HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₂₆H₂₇O₄ 403.1909; found, 403.1916.

(2R,3S,6S)-3-(Benzyloxy)-2-(benzyloxymethyl)-6-p-tolyldihydro-2H-pyran-4(3H)-one [3by]

The compound **3by** was prepared using the general procedure. The reaction was carried out between tri-*O*-benzyl-D-galactal **1af** (100 mg, 0.24 mmol) and 4-methylbenzenediazonium tetrafluoroborate **2ae** (55 mg, 0.27 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.024 mmol) at room temperature for 4 h. Column chromatography purification was performed using 10 % ethyl acetate in hexane which furnished **3by** as semi solid (52 mg, 52%); TLC R_f = 0.47 (15 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.27-7.14 (m, 13H), 7.08 (d, *J* = 7.5 Hz, 2H), 5.22 (d, *J* = 9.0 Hz, 1H), 4.85 (d, *J* = 12.5 Hz, 1H), 4.49 (d, *J* = 13.0 Hz, 2H), 4.42 (d, *J* = 12.5 Hz, 1H), 4.34 (s, 1H), 4.08 (d, *J* = 6.0 Hz, 1H), 3.77-3.70 (m, 2H), 2.74-2.71 (m, 1H), 2.60-2.55 (m, 1H), 2.25 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 204.3, 137.9, 137.8, 137.4, 137.4, 129.2, 128.4, 128.3, 127.9, 127.8, 127.6, 127.5, 126.0, 79.2, 76.3, 74.7, 73.5, 72.6, 68.4, 47.8, 21.1 HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₂₇H₂₉O₄ 417.2066; found, 417.2061.

(2R,3S,6S)-3-(Benzyloxy)-2-(benzyloxymethyl)-6-(4-bromophenyl)dihydro-2H-pyran-4(3H)-one [3bz]

The compound **3bz** was prepared using the general procedure. The reaction was carried out between tri-*O*-benzyl-D-galactal **1af** (100 mg, 0.24 mmol) and 4-bromobenzenediazonium tetrafluoroborate **2aa** (72 mg, 0.27 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (5.5 mg, 0.024 mmol) at room temperature for 4 h. Column chromatography purification was performed using 10 % ethyl acetate in hexane which furnished **3bz** as yellowish foam (58 mg, 50%); TLC R_f = 0.50 (15 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.50 (d, *J* = 8.0 Hz, 2H), 7.39-7.28 (m, 11H), 7.23 (d, *J* = 8.0 Hz, 2H), 5.31 (dd, *J* = 10.0, 3.0 Hz, 1H), 4.97 (d, *J* = 12.0 Hz, 1H), 4.62-4.58 (m, 2H), 4.52 (d, *J* = 12.5 Hz, 1H), 4.46 (s, 1H), 4.18 (d, *J* = 6.5 Hz, 1H), 3.88-3.81 (m, 2H), 2.81 (dd, *J* = 14.5, 3.0 Hz, 1H), 2.62-2.57 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 203.7, 139.6, 137.8, 137.3, 131.6, 128.5, 128.3, 128.0, 127.8, 127.6, 127.6, 121.8, 79.0, 76.5, 74.1, 73.6, 72.7, 68.5, 47.8. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₂₆H₂₆BrO₄ 481.1014; found, 481.1019.

(2S,3S,6R)-3-(Benzyloxy)-2-methyl-6-phenyldihydro-2H-pyran-4(3H)-one [3ca]

The compound **3ca** was prepared using the general procedure. The reaction was carried out between 3,4-di-*O*-benzyl-L-rhamnal **1ag** (110 mg, 0.35 mmol) and benzenediazonium tetrafluoroborate **2ac** (75 mg, 0.4 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (8 mg, 0.035 mmol) at room temperature for 1.5 h. Column chromatography purification was performed using 8 % ethyl acetate in hexane which furnished **3ca** as white foam (73 mg, 69%); TLC R_f = 0.25 (15 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.42-7.28 (m, 10H), 5.33 (t, *J* = 4.0 Hz, 1H), 4.89 (d, *J* = 11.5 Hz, 1H), 4.52 (d, *J* = 11.5 Hz, 1H), 3.87-3.84 (m, 1H), 3.70 (d, *J* = 7.5 Hz, 1H), 3.18 (dd, *J* = 14.0, 3.5 Hz, 1H), 2.96 (dd, *J* = 14.5, 6.5 Hz, 1H), 1.33 (d, *J* = 6.3 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 206.3, 139.0, 137.2, 128.6, 128.3, 128.1, 128.0, 127.9, 127.1, 84.7, 74.6, 73.0, 71.9, 44.4, 18.0. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₉H₂₁O₃ 297.1491; found, 297.1499.

(2S,3S,6R)-3-(Benzyloxy)-2-methyl-6-p-tolyldihydro-2H-pyran-4(3H)-one [3cb]

The compound **3cb** was prepared using the general procedure. The reaction was carried out between 3,4-di-*O*-benzyl-L-rhamnal **1ag** (110 mg, 0.35 mmol) and 4-methylbenzenediazonium tetrafluoroborate **2ae** (81 mg, 0.4 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (8 mg, 0.035 mmol) at room temperature for 1.5 h. Column chromatography purification was performed using 8 % ethyl acetate in hexane which furnished **3cb** as white foam (79 mg, 72%); TLC R_f = 0.40 (15 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.27-7.19 (m, 7H), 7.07 (d, *J* = 7.5 Hz, 2H), 5.20 (m, 1H), 4.78 (d, *J* = 11.5 Hz, 1H), 4.41 (d, *J* = 11.5 Hz, 1H), 3.73-3.70 (m, 1H), 3.58 (d, *J* = 8.0 Hz, 1H), 3.05 (d, *J* = 14.0 Hz, 1H), 2.85 (dd, *J* = 14.0, 6.5 Hz, 1H), 2.24 (s, 3H), 1.21 (m, *J* = 7.4 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 206.6, 137.9, 137.3, 136.0, 129.3, 128.4, 128.2, 128.0, 127.2, 84.8, 74.6, 73.0, 71.6, 44.5, 21.0, 18.2. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₂₀H₂₃O₃ 311.1647; found, 311.1639.

(2S,3S,6R)-3-(Benzyloxy)-2-methyl-6-(4-nitrophenyl)dihydro-2H-pyran-4(3H)-one [3cc]

The compound **3cc** was prepared using the general procedure. The reaction was carried out between 3,4-di-*O*-benzyl-L-rhamnal **1ag** (110 mg, 0.35 mmol) and 4-nitrobenzenediazonium tetrafluoroborate **2ag** (93 mg, 0.4 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (8 mg, 0.035 mmol) at room temperature for 1.5 h. Column chromatography purification was performed using 12 % ethyl acetate in hexane which furnished **3cc** as white foam (78 mg, 64%); TLC R_f = 0.24 (15 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 8.19 (d, *J* = 8.5 Hz, 2H), 7.55 (d, *J* = 8.5 Hz, 2H), 7.34-7.28 (m, 5H), 5.29 (t, *J* = 2.5 Hz, 1H), 4.79 (d, *J* = 11.5 Hz, 1H), 4.46 (d, *J* = 11.5 Hz, 1H), 3.88-3.84 (m, 1H), 3.66 (d, *J* = 6.5 Hz, 1H), 3.11 (dd, *J* = 14.0, 5.0 Hz, 1H), 2.91 (dd, *J* = 14.0, 6.0 Hz, 1H), 1.29 (d, *J* = 6.5 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 205.4, 147.6, 146.4, 136.9, 128.4, 128.2, 128.1, 127.7, 123.8, 84.1, 73.6, 73.2, 72.9, 44.5, 17.5. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₉H₂₀NO₅ 342.1341; found, 342.1341.

(2S,5R)-5-(Benzyloxy)-2-p-tolyldihydro-2H-pyran-4(3H)-one [3cd]

The compound **3cd** was prepared using the general procedure. The reaction was carried out between di-*O*-benzyl-D-xylal **1ah** (110 mg, 0.37 mmol) and 4-methylbenzenediazonium tetrafluoroborate **2ae** (85 mg, 0.56 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (8.5 mg, 0.037 mmol) at room temperature for 4 h. Column chromatography purification was performed using 8 % ethyl acetate in hexane which furnished **3cd** as colourless semi solid (45 mg, 41%); TLC R_f = 0.24 (15 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.39-7.28 (m, 7H), 7.21 (d, *J* = 8.0 Hz, 2H), 4.73-4.69 (m, 2H), 4.53 (d, *J* = 12.0 Hz, 1H), 4.33 (dd, *J* = 12.5, 2.5 Hz, 1H), 3.86-3.83 (m, 1H), 3.75 (s, 1H), 3.20 (dd, *J* = 13.5, 10.0 Hz, 1H), 2.63 (d, *J* = 13.5 Hz, 1H), 2.37 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 206.4, 138.0, 137.0, 129.3, 128.5, 128.1, 128.1, 126.0, 80.1, 79.6, 71.7, 70.5, 47.2, 21.1. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₉H₂₁O₃ 297.1491; found, 297.1501.

(2R,5S)-2-(Benzyloxymethyl)-5-p-tolyldihydrofuran-3(2H)-one [3ce]

The compound **3ce** was prepared using the general procedure. The reaction was carried out between di-*O*-benzyl-D-ribal **1ai** (100 mg, 0.34 mmol) and 4-methylbenzenediazonium tetrafluoroborate **2ae** (77 mg, 0.37 mmol) in acetonitrile-water (4 mL, 3:1) in the presence of Pd(OAc)₂ (8 mg, 0.034 mmol) at room temperature for 2.5 h. Column chromatography purification was performed using 8 % ethyl acetate in hexane which furnished **3ce** as white foam (31 mg, 31%); TLC R_f = 0.25 (15 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.31-7.24 (t, 5H), 7.14 (d, *J* = 7.5 Hz, 2H), 7.09 (d, *J* = 7.5 Hz, 2H), 4.86 (d, *J* = 12.0 Hz, 1H), 4.54-4.51 (m, 2H), 4.35-4.32 (m, 1H), 4.13-4.09 (m, 1H), 3.54 (t, *J* = 11.0 Hz, 1H), 2.66-2.59 (m, 2H), 2.26 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 204.9, 138.0, 137.3, 136.8, 129.3, 128.5, 128.4, 128.0, 127.9, 125.5, 80.6, 78.9, 72.7, 70.5, 49.7, 21.1. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₉H₂₁O₃ 297.1491; found, 297.1482.

(2R,3R,6S)-6-(2-Chlorophenyl)-3,4,4-trimethoxy-2-(methoxymethyl)tetrahydro-2H-pyran [4ab]

The compound **4ab** was prepared using the general procedure while methanol is used as the solvent. The reaction was carried out between tri-*O*-methyl-D-glucal **1aa** (95 mg, 0.5 mmol) and 2-chlorobenzenediazonium tetrafluoroborate **2ab** (127 mg, 0.56 mmol) in methanol (4 mL) in the

presence of Pd(OAc)₂ (5.6 mg, 0.025 mmol) at room temperature for 1 h. Column chromatography purification was performed using 15 % ethyl acetate in hexane which furnished **3ab** as viscous liquid (157 mg, 94%); TLC R_f = 0.38 (35 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.60 (d, *J* = 7.5 Hz, 1H), 7.23-7.18 (m, 2H), 7.10 (t, *J* = 7.5 Hz, 1H), 4.98 (d, *J* = 11.5 Hz, 1H), 4.40 (t, *J* = 6.0 Hz, 1H), 3.80-3.77 (m, 1H), 3.52 (dd, *J* = 10.5, 5.0 Hz, 1H), 3.43 (s, 3H), 3.32 (s, 3H), 3.27 (s, 3H), 3.18 (s, 4H), 2.06 (d, *J* = 14.0 Hz, 1H), 1.68 (t, *J* = 13.0 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 139.1, 131.2, 128.9, 128.4, 127.8, 127.2, 98.7, 75.7, 74.5, 70.6, 67.0, 59.0, 57.3, 47.7, 47.5, 34.1. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₁₆H₂₄ClO₅ 331.1312; found, 331.1331.

Procedure for the deprotection of dimethyl acetal **4ab**:

To a solution of acetal **4ab** (76 mg 0.23 mmol) in methanol (2 mL), 6N HCl (5 mL) was added at room temperature and stirred for 1h. The resulting solution was diluted with ethyl acetate (100 mL) and washed with saturated NaHCO₃ and brine solutions. The organic layer was dried over anhydrous Na₂SO₄, concentrated and purified by column chromatography using 15 % ethyl acetate in hexane which furnished a mixture of inseparable **3ab** and **5ab** (α/β =6:1) in 76% yield (51 mg).

(2R,3S,4S,6S)-3-(benzyloxy)-2-(benzyloxymethyl)-6-phenyltetrahydro-2H-pyran-4-ol [**4ba**]

To a stirred solution of ketone **3ba** (150 mg, 0.37 mmol) in methanol (7 mL), sodium borohydride (15 mg, 0.4 mmol) was added at 0-4 °C. The reaction mixture was stirred for 30 mins at the same temperature, diluted with ethyl acetate (50 mL) and washed with saturated ammonium chloride solution. The organic layer was dried over anhydrous Na₂SO₄, concentrated and purified in column chromatography using 15 % ethyl acetate in hexane which furnished **4ba** as a white foam in 72% yield (108 mg). TLC R_f = 0.25 (20 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.32-7.16 (m, 15H), 4.67-4.64 (m, 2H), 4.52-4.44 (m, 3H), 4.29 (s, 1H), 4.03-4.01 (m, 1H), 3.68-3.63 (m, 3H), 2.01-1.99 (m, 2H), 1.92 (d, *J* = 13.0 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 141.7, 137.8, 137.8, 128.4, 128.4, 128.2, 127.8, 127.8, 127.7, 127.6, 127.4, 126.0, 75.4, 73.4, 73.0, 72.6, 71.5, 69.2, 66.0, 36.6. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₂₆H₂₉O₄ 405.2066; found, 405.2019.

(2R,3S,4S,6S)-3-(benzyloxy)-2-(benzyloxymethyl)-6-(4-bromophenyl)tetrahydro-2H-pyran-4-ol [4bf]

To a stirred solution of ketone **3bf** (100 mg, 0.21 mmol) in methanol (7 mL), sodium borohydride (11 mg, 0.28 mmol) was added at 0-4 °C. The reaction mixture was stirred for 30 mins at the same temperature, diluted with ethyl acetate (50 mL) and washed with saturated ammonium chloride solution. The organic layer was dried over anhydrous Na₂SO₄, concentrated and purified in column chromatography using 20 % ethyl acetate in hexane which furnished **4bf** as viscous oil in 82% yield (83 mg). TLC R_f = 0.26 (15 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.35 (d, *J* = 7.5 Hz, 2H), 7.25-7.18 (m, 12H), 4.63 (d, *J* = 10.5 Hz, 2H), 4.50 (d, *J* = 12 Hz, 1H), 4.44 (d, *J* = 12.5 Hz, 1H), 4.22 (s, 1H), 4.02-4.01 (m, 1H), 3.65-3.61 (m, 3H), 2.14 (bs, 1H), 2.01-1.88 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 140.8, 137.7, 137.7, 131.2, 128.5, 128.4, 127.9, 127.8, 127.7, 127.6, 121.1, 75.3, 73.4, 72.4, 72.3, 71.5, 69.1, 65.8, 36.3. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₂₆H₂₈BrO₄ 483.1171; found, 483.1163.

(2R,3S,4S,6S)-3,4-bis(benzyloxy)-2-(benzyloxymethyl)-6-phenyltetrahydro-2H-pyran (5ba)

The alcohol **4ba** (100 mg, 0.25 mmol) was stirred in dry DMF (3 mL) was added and cooled to 0 °C after which NaH (12 mg, 60% in mineral oil) was added. The mixture was stirred for 5 min at the same temperature to which benzyl bromide (0.038 mL, 1.5 equiv.) was added. The resulting mixture was stirred for 60 mins and quenched by saturated aqueous NH₄Cl (1 mL) and diluted with ethyl acetate (50 mL). The organic phase was washed with H₂O, brine, dried over anhydrous Na₂SO₄ and evaporated under reduced pressure. The crude product was purified by column chromatography using 10% ethyl acetate in hexane to afford **5ba** as viscous oil in 81% yield (100 mg). TLC R_f = 0.34 (20 % ethyl acetate in hexane); ¹H NMR (500 MHz, CDCl₃) δ 7.45-7.28 (m, 20H), 4.78-4.75 (m, 3H), 4.55 (d, *J* = 17.5 Hz, 4H), 4.47 (s, 1H), 4.95 (d, *J* = 10 Hz, 1H), 3.91 (s, 1H), 3.75-3.68 (m, 2H), 2.45-2.38 (m, 1H), 2.04 (d, *J* = 12.5 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 141.9, 138.6, 138.4, 137.9, 128.40, 128.2, 128.2, 127.8, 127.6, 127.5, 127.4, 127.3, 126.0, 74.5, 73.7, 73.5, 73.2, 72.6, 71.6, 70.0, 68.9, 33.7. HRMS (ESI-TOF) (*m/z*): [M + H]⁺ calcd for C₃₃H₃₅O₄ 495.2535; found, 495.2515.

References

1. B. Wang, D. C. Xiong, X. S. Ye, Direct C-H trifluoromethylation of glycals by photoredox catalysis. *Org. Lett.*, 2015, **17**, 5698-5701.
2. M. G. Beaver, K. A. Woerpel, Erosion of stereochemical control with increasing nucleophilicity: *O*-glycosylation at the diffusion limit. *J. Org. Chem.*, 2010, **75**, 1107-1118.
3. D. Lafont, G. Descotes, Synthesis of 2-deoxy-2-iodoglycosyl phosphoramidates. *Carbohydr. Res.*, 1987, **166**, 195-209.
4. (a) H. S. Chen, T. Xian, W. Zhang, W. S. Si, X. S. Luo, B. Zhang, M. Y. Zhang, Z. F. Wang, J. B. Zhang, An efficient method for the synthesis of pyranoid glycals. *Carbohydr. Res.*, 2016, **431**, 42-46. (b) S. K. Madhusudan, G. Agnihotri, D. S. Negi, A. K. Misra, Direct one-pot conversion of acylated carbohydrates into their alkylated derivatives under heterogeneous reaction conditions using solid NaOH and a phase transfer catalyst. *Carbohydr. Res.*, 2005, **340**, 1373-1377.
5. P. W. Moore, J. K. Schuster, R. J. Hewitt, M. R. L. Stone, P. H. Teesdale-Spittle, J. E. Harvey, Divergent synthesis of 2-*C*-branched pyranosides and oxepines from 1,2-gem-dibromocyclopropyl carbohydrates. *Tetrahedron* 2014, **70**, 7032-7043.
6. R. A. Brawn, J. S. Panek, Stereoselective *C*-glycosidations with achiral and enantioenriched allenylsilanes. *Org. Lett.*, 2010, **12**, 4624-4627.
7. F. Bravo, M. Kassou, Y. Diaz, S. Castillon, Synthesis of erythro and threo furanoid glycals from 1-and 2-phenylselenenyl-carbohydrate derivatives. *Carbohydr. Res.*, 2001, **336**, 83-97.
8. P. S. Gribanov, M. A. Topchiy, Y. D. Golenko, Y. I. Lichtenstein, A. V. Eshtukov, V. E. Terekhov, A. F. Asachenko, M. S. Nechaev, An unprecedentedly simple method of synthesis of aryl azides and 3-hydroxytriazenes. *Green. Chem.*, 2016, **18**, 5984-5988.
9. Z. Y. Tang, Y. Zhang, T. Wang, W. Wang, Rhodium(I)-catalyzed synthesis of aryltriethoxysilanes from arenediazonium tosylate salts with triethoxysilane. *Synlett* 2010, 804-808.
10. S. M. Dirk, S. Pylypenko, S. W. Howell, J. E. Fulghum, D. R. Wheeler, Potential-directed assembly of aryl iodonium salts onto silicon {100} hydride terminated and platinum surfaces. *Langmuir* 2005, **21**, 10899-901.

11. A. Prechter, M. Heinrich, Hydrogen peroxide and arenediazonium salts as reagents for a radical Beckmann-type rearrangement. *Synthesis* 2011, 1515-1525.
12. H. Bonin, D. Delbrayelle, P. Demonchaux, E. Gras, Base free aryl coupling of diazonium compounds and boronic esters: self-activation allowing an overall highly practical process. *Chem. Commun.*, 2010, **46**, 2677-2679.
13. B. Ceken, M. Kizil, Synthesis and DNA-cleaving activity of a series of substituted arenediazonium ions. *Russ. J. Bioorg. Chem.*, 2008, **34**, 488-498.
14. H. L. Qin, Q. H. Zheng, G. A. L. Bare, P. Wu, K. B. Sharpless, A Heck-Matsuda process for the synthesis of arylenesulfonyl fluorides: selectively addressable bis-electrophiles for sufix click chemistry. *Angew. Chem., Int. Edit.*, 2016, **55**, 14155-14158.
15. R. J. A. Nabuurs, V. V. Kapoerchan, A. Metaxas, S. de Jongh, M. de Backer, M. M. Welling, W. Jiskoot, A. D. Windhorst, H. S. Overkleeft, M. A. van Buchem, M. Overhand, L. van der Weerd, Polyfluorinated bis-styrylbenzenes as amyloid-beta plaque binding ligands. *Bioorgan. Med. Chem.*, 2014, **22**, 2469-2481.
16. W. Erb, A. Hellal, M. Albini, J. Rouden, J. Blanchet, An easy route to (hetero) arylboronic acids. *Chem-Eur. J.*, 2014, **20**, 6608-6612.
17. C. C. Oliveira, E. A. dos Santos, J. H. Nunes, C. R. Correia, Stereoselective arylation of substituted cyclopentenes by substrate-directable Heck-Matsuda reactions: a concise total synthesis of the sphingosine 1-phosphate receptor (S1P(1)) agonist VPC01091. *J. Org. Chem.*, 2012, **77**, 8182-90.




Figure S1: ¹H-NMR spectrum of compound **1aa** in CDCl₃




Figure S2: ^{13}C -NMR spectrum of compound 1aa in CDCl_3




Figure S3: ^1H -NMR spectrum of compound 1ab in CDCl_3




Figure S4: ^{13}C -NMR spectrum of compound **1ab** in CDCl_3 .




Figure S5: ^1H -NMR spectrum of compound **1ac** in CDCl_3




Figure S6: ^{13}C -NMR spectrum of compound **1ac** in CDCl_3 .




Figure S7: ^1H -NMR spectrum of compound **1ad** in CDCl₃




Figure S8: ¹³C-NMR spectrum of compound 1ad in CDCl₃




Figure S9: ^1H -NMR spectrum of compound **1af** in CDCl₃




Figure S10: ¹³C-NMR spectrum of compound **1af** in CDCl₃




Figure S11: ^1H -NMR spectrum of compound **1ag** in CDCl_3




Figure S12: ^{13}C -NMR spectrum of compound **1ag** in CDCl_3




Figure S13: ¹H-NMR spectrum of compound 1ah in CDCl₃




Figure S14: ¹³C-NMR spectrum of compound **1ah** in CDCl₃




Figure S15: ¹H-NMR spectrum of compound 1ai in CDCl₃




Figure S16: ^{13}C -NMR spectrum of compound **1ai** in CDCl_3




Figure S17: ¹H-NMR spectrum of compound **1aj** in CDCl₃




Figure S18: ^{13}C -NMR spectrum of compound **1aj** in CDCl_3




Figure S19: ¹H-NMR spectrum of compound 3aa in CDCl₃




Figure S20: ^{13}C -NMR spectrum of compound **3aa** in CDCl_3




Figure S21: ¹H-NMR spectrum of compound 3ab in CDCl₃




Figure S22: ^{13}C -NMR spectrum of compound **3ab** in CDCl_3




Figure S23: ^1H -NMR spectrum of compound 3ac in CDCl_3




Figure S24: ^{13}C -NMR spectrum of compound **3ac** in CDCl_3




Figure S25: ^1H -NMR spectrum of compound **3ad** in CDCl₃




Figure S26: ^{13}C -NMR spectrum of compound **3ad** in CDCl_3




Figure S27: ¹H-NMR spectrum of compound **3ae** in CDCl₃




Figure S28: ^{13}C -NMR spectrum of compound **3ae** in CDCl_3




Figure S29: ¹H-NMR spectrum of compound 3af in CDCl₃

SI-67




Figure S30: ^{13}C -NMR spectrum of compound **3af** in CDCl_3
SI-68




Figure S31: ¹H-NMR spectrum of compound **3ag** in CDCl₃




Figure S32: ¹³C-NMR spectrum of compound **3ag** in CDCl₃




Figure S33: ^1H -NMR spectrum of compound **3ah** in CDCl_3




Figure S34: ^{13}C -NMR spectrum of compound **3ah** in CDCl_3




Figure S35: ^1H -NMR spectrum of compound **3ai** in CDCl_3




Figure S36: ¹³C-NMR spectrum of compound **3ai** in CDCl₃




Figure S37: ¹H-NMR spectrum of compound **3aj** in CDCl₃




Figure S38: ¹³C-NMR spectrum of compound **3aj** in CDCl₃




Figure S39: ^1H -NMR spectrum of compound **3ak** in CDCl_3




Figure S40: ^{13}C -NMR spectrum of compound **3ak** in CDCl_3




Figure S41: ¹H-NMR spectrum of compound **3al** in CDCl₃




Figure S42: ¹³C-NMR spectrum of compound 3al in CDCl₃




Figure S43: ¹H-NMR spectrum of compound 3am in CDCl₃




Figure S44: ^{13}C -NMR spectrum of compound 3am in CDCl_3




Figure S45: ¹H-NMR spectrum of compound 3an in CDCl₃




Figure S46: ^{13}C -NMR spectrum of compound 3an in CDCl_3




Figure S47: ¹H-NMR spectrum of compound **3ao** in CDCl₃




Figure S48: ¹³C-NMR spectrum of compound **3ao** in CDCl₃




Figure S49: ^1H -NMR spectrum of compound **3ap** in CDCl₃




Figure S50: ^{13}C -NMR spectrum of compound **3ap** in CDCl₃




Figure S51: ¹H-NMR spectrum of compound **3aq** in CDCl₃




Figure S52: ^{13}C -NMR spectrum of compound **3aq** in CDCl_3




Figure S53: ¹H-NMR spectrum of compound **3ar** in CDCl₃




Figure S54: ^{13}C -NMR spectrum of compound **3ar** in CDCl_3




Figure S55: ^1H -NMR spectrum of compound **3as** in CDCl_3




Figure S56: ¹³C-NMR spectrum of compound **3as** in CDCl₃




Figure S57: ¹H-NMR spectrum of compound **3at** in CDCl₃




Figure S58: ^{13}C -NMR spectrum of compound **3at** in CDCl_3




Figure S59: ¹H-NMR spectrum of compound **3au** in CDCl₃




Figure S60: ¹³C-NMR spectrum of compound 3au in CDCl₃




Figure S61: ¹H-NMR spectrum of compound **3av** in CDCl₃




Figure S62: ^{13}C -NMR spectrum of compound **3av** in CDCl₃




Figure S63: ^1H -NMR spectrum of compound **3aw** in CDCl_3




Figure S64: ^{13}C -NMR spectrum of compound **3aw** in CDCl_3




Figure S65: ¹H-NMR spectrum of compound **3ax** in CDCl₃




Figure S66: ¹³C-NMR spectrum of compound 3ax in CDCl₃




Figure S67: ¹H-NMR spectrum of compound **3ay** in CDCl₃




Figure S68: ^{13}C -NMR spectrum of compound **3ay** in CDCl_3




Figure S69: ^1H -NMR spectrum of compound **3az** in CDCl_3




Figure S70: ^{13}C -NMR spectrum of compound **3az** in CDCl_3




Figure S71: ^1H -NMR spectrum of compound **3ba** in CDCl_3




Figure S72: ^{13}C -NMR spectrum of compound 3ba in CDCl_3




Figure S73: ¹H-NMR spectrum of compound **3bb** in CDCl₃




Figure S74: ^{13}C -NMR spectrum of compound **3bb** in CDCl_3




Figure S75: ^1H -NMR spectrum of compound 3bc in CDCl_3




Figure S76: ^{13}C -NMR spectrum of compound **3bc** in CDCl_3




Figure S77: ^1H -NMR spectrum of compound **3bd** in CDCl_3




Figure S78: ^{13}C -NMR spectrum of compound **3bd** in CDCl_3




Figure S79: ¹H-NMR spectrum of compound **3be** in CDCl₃




Figure S80: ¹³C-NMR spectrum of compound 3be in CDCl₃




Figure S81: ^1H -NMR spectrum of compound **3bf** in CDCl_3




Figure S82: ¹³C-NMR spectrum of compound 3bf in CDCl₃
SI-120




Figure S83: ¹H-NMR spectrum of compound 3bg in CDCl₃




Figure S84: ^{13}C -NMR spectrum of compound **3bg** in CDCl_3




Figure S85: ^1H -NMR spectrum of compound 3bh in CDCl_3




Figure S86: ¹³C-NMR spectrum of compound 3bh in CDCl₃




Figure S87: ^1H -NMR spectrum of compound **3bi** in CDCl₃




Figure S88: ^{13}C -NMR spectrum of compound **3bi** in CDCl_3




Figure S89: ^1H -NMR spectrum of compound **3bj** in CDCl_3




Figure S90: ^{13}C -NMR spectrum of compound 3bj in CDCl_3




Figure S91: ^1H -NMR spectrum of compound **3bl** in CDCl_3




Figure S92: ^{13}C -NMR spectrum of compound **3bl** in CDCl_3




Figure S93: ¹H-NMR spectrum of compound **3bm** in CDCl₃




Figure S94: ^{13}C -NMR spectrum of compound **3bm** in CDCl_3




Figure S95: ¹H-NMR spectrum of compound **3bn** in CDCl₃




Figure S96: ¹³C-NMR spectrum of compound **3bn** in CDCl₃




Figure S97: ¹H-NMR spectrum of compound **3bo** in CDCl₃




Figure S98: ^{13}C -NMR spectrum of compound **3bo** in CDCl_3




Figure S99: ^1H -NMR spectrum of compound 3bp in CDCl_3




Figure S100: ^{13}C -NMR spectrum of compound **3bp** in CDCl_3 .




Figure S101: ¹H-NMR spectrum of compound **3bq** in CDCl₃




Figure S102: ^{13}C -NMR spectrum of compound **3bq** in CDCl_3




Figure S103: ¹H-NMR spectrum of compound 3br in CDCl₃




Figure S104: ^{13}C -NMR spectrum of compound **3br** in CDCl_3




Figure S105: ¹H-NMR spectrum of compound **3bs** in CDCl₃




Figure S106: ^{13}C -NMR spectrum of compound 3bs in CDCl_3




Figure S107: ¹H-NMR spectrum of compound **3bt** in CDCl₃




Figure S108: ^{13}C -NMR spectrum of compound 3bt in CDCl_3




Figure S109: ¹H-NMR spectrum of compound 3bu in CDCl₃




Figure S110: ^{13}C -NMR spectrum of compound **3bu** in CDCl₃

SI-148




Figure S111: ^1H -NMR spectrum of compound **3bv** in CDCl_3




Figure S112: ^{13}C -NMR spectrum of compound **3bv** in CDCl_3




Figure S113: ^1H -NMR spectrum of compound 3bw in CDCl_3




Figure S114: ^{13}C -NMR spectrum of compound 3bw in CDCl_3




Figure S115: ^1H -NMR spectrum of compound **3bx** in CDCl_3




Figure S116: ^{13}C -NMR spectrum of compound **3bx** in CDCl_3




Figure S117: ¹H-NMR spectrum of compound **3by** in CDCl₃




Figure S118: ^{13}C -NMR spectrum of compound **3by** in CDCl_3




Figure S119: ^1H -NMR spectrum of compound 3bz in CDCl_3




Figure S120: ¹³C-NMR spectrum of compound 3bz in CDCl₃




Figure S121: ^1H -NMR spectrum of compound 3ca in CDCl_3




Figure S122: ^{13}C -NMR spectrum of compound **3ca** in CDCl₃




Figure S123: ¹H-NMR spectrum of compound **3cb** in CDCl₃




Figure S124: ^{13}C -NMR spectrum of compound **3cb** in CDCl_3




Figure S125: ^1H -NMR spectrum of compound **3cc** in CDCl_3




Figure S126: ^{13}C -NMR spectrum of compound **3cc** in CDCl_3




Figure S127: ¹H-NMR spectrum of compound **3cd** in CDCl₃




Figure S128: ^{13}C -NMR spectrum of compound **3cd** in CDCl_3




Figure S129: ^1H -NMR spectrum of compound **3ce** in CDCl₃




Figure S130: ^{13}C -NMR spectrum of compound **3ce** in CDCl_3




Figure S131: ^1H -NMR spectrum of compound 4ab in CDCl_3




Figure S132: ¹³C-NMR spectrum of compound 4ab in CDCl₃




Figure S133: ¹H-NMR spectrum of compound 4ba in CDCl₃




Figure S134: ¹³C-NMR spectrum of compound 4ba in CDCl₃




Figure S135: ^1H -NMR spectrum of compound **4bf** in CDCl_3




Figure S136: ¹³C-NMR spectrum of compound **4bf** in CDCl₃




Figure S137: ^1H -NMR spectrum of compound 5ab in CDCl_3
SI-175




Figure S138: ^{13}C -NMR spectrum of compound **5ab** in CDCl_3




Figure S139: ¹H-NMR spectrum of compound 3ab+5ab in CDCl₃




Figure S140: ¹³C-NMR spectrum of compound 3ab+5ab in CDCl₃